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The thesis showed that the rate 
of hyaluronan (HA) synthesis in 
different cell types correlated with 
the cellular content of UDP-GlcNAc 
and UDP-GlcUA. UDP-GlcNAc 
controlled HA synthesis as a critical 
substrate for HA synthases (HAS1-3) 
but also by regulating HAS expression 
through O-GlcNAc modification of 
transcription factors. Mannose was 
found to inhibit HA synthesis by 
UDP-GlcNAc depletion. This novel 
inhibitor blocked HA-dependent 
monocyte binding to keratinocytes, 
induced by inflammation, and 
prevented leukocyte accumulation 
and growth in wound tissue. 
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ABSTRACT 
 
Hyaluronan is a large glycosaminoglycan consisting of alternating N-
acetylglucosamine (GlcNAc) and glucuronic acid (GlcUA) units. It is 
synthesized by hyaluronan synthase enzymes (HAS1,2,3). In many tissues 
hyaluronan is a major component of the extracellular matrix. It enhances cell 
proliferation, migration, and controls differentiation. High hyaluronan levels 
are associated with cancer progression and inflammation. In this study a new 
inhibitor of the hyaluronan synthesis, mannose, was discovered and it was 
demonstrated that it depletes content of UDP-GlcNAc. The three HAS 
enzymes showed different sensitivities to the cellular content of the UDP-
GlcNAc.  HAS3 had the highest affinity to the precursors and HAS1 the 
lowest, suggesting that the HAS-isoenzyme distribution in a particular cell 
type determines the sensitivity of its hyaluronan synthesis to UDP-sugar 
supply. Interestingly, a feedback mechanism from UDP-sugar content to 
HAS2 expression was found since fluctuations in UDP-GlcNAc content 
caused reciprocal changes in HAS2 transcription. This regulation is likely 
mediated by O-GlcNAc modifications of transcription factors YY1 and SP1. 
This study also showed that the hyaluronan-dependent binding of leukocytes 
can be induced by the inflammatory mediators and cell stress, and inhibited 
with mannose. In an in vivo wound model mannose reduced the hyaluronan 
level, granulation tissue growth and accumulation of leukocytes. Altogether, 
this work shows that cellular UDP-sugar content regulates hyaluronan 
synthesis and hyaluronan-mediated functions, such as cell migration, 
proliferation, and leukocyte adhesion. Therefore, inhibition of hyaluronan 
synthesis by reduction of UDP-GlcNAc using mannose or similar effectors 
may provide novel ways to treat pathological processes that involve excessive 
hyaluronan production, e.g. in inflammation and cancer. 
 
National Library of Medical Classification: 
Medical Subject Headings: Hyaluronan, UDP-sugars, inflammation 
V 
 
Jokela, Tiina. UDP-sokerit säätelevät hyaluronaani synteesiä 
University of Eastern Finland, Faculty of Health Sciences, 2011 
Publications of the University of Eastern Finland. Dissertations in Health Sciences  
Numero 89. 2011. 78 s. 
 
ISBN (print): 978-952-61-0625-0 
ISBN (pdf): 978-952-61-0626-7 
ISSN (print): 1798-5706 
ISSN (pdf): 1798-5714 
ISSN-L: 1798-5706 
 
TIIVISTELMÄ 
 
Hyaluronaani on suuri glykosaminoglykaani joka koostuu vuorottelevista N-
asetyyliglukosamiinin (GlcNAc) ja glukuronihapon (GlcUA) muodostamista 
sokeriyksiköistä. Hyaluronaanisyntaasien (HAS1,2,3) tuottama hyaluronaani 
on monissa kudoksissa soluvälitilan tärkeimpiä rakennusaineita. 
Hyaluronaani edistää solujen jakaantumista ja liikkumista, sekä säätelee 
erilaistumista.  Liiallista hyaluronaanin tuotantoa esiintyy monissa syövissä ja 
tulehdussairauksissa. Tässä tutkimuksessa kuvataan uusi 
hyaluronaanisynteesin inhibiittori – mannoosi – jonka vaikutus perustuu sen 
kykyyn vähentää solunsisäistä UDP-GlcNAc-pitoisuutta. Työ osoitti myös 
että HAS isoentsyymit tarvitsivat erilaiset UDP-sokeripitoisuudet 
tuottaakseen maksimaalisesti hyaluronaania, HAS3 pystyi tähän pienimmällä 
pitoisuudella ja HAS1 tarvitsi suurimman pitoisuuden UDP-sokereita. Yksi 
mielenkintoisimmista löydöksistä oli takaisinsäätelymekanismi, jossa UDP-
GlcNAc:n pitoisuuden muutos aiheutti päinvastaisen muutoksen HAS2-
geenin ilmenemisessä. Tulokset viittaavat siihen että tässä 
säätelymekanismissa on mukana transkriptiotekijät YY1 ja SP1, sekä niihin 
sitoutuva O-GlcNAc. Tässä työssä osoitettiin myös että tulehduksen 
välittäjäaineet ja solustressi lisäsivät hyaluronaanista riippuvaa monosyyttien 
sitoutumista keratinosyytteihin, ja että tämä sitoutuminen estyi mannoosilla. 
Myös in vivo haavamallissa mannoosi-injektiot vähensivät hyaluronaanin 
määrää, estivät granulaatiokudoksen muodostumista ja rajoittivat 
leukosyyttien määrää haava-alueella. Tässä työssä osoitettiin että UDP-
sokerisubstraattien konsentraatiota kontrolloimalla voidaan säädellä 
hyaluronaanin synteesiä ja hyaluronaanin välittämiä solun toimintoja, kuten 
kasvua, liikkumista ja valkosolujen sitoutumista. Mannoosi, uusi 
hyaluronaanisynteesin inhibiittori, tai vastaava UDP-GlcNAc:in 
konsentraatiota vähentävä tekijä voi löytää käyttökohteita tulehduksen ja 
syövän hoidossa. 
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1 Introduction 
Hyaluronan is a large glycosaminoglycan localized mainly in the extracellular 
space. Due to its anionic nature hyaluronan is strongly hydrophilic and acts 
as a space filler in tissues. Interestingly, hyaluronan also has special 
properties: it can regulate cell proliferation, migration, invasion and 
differentiation just by expanding the space inside the tissue or activating 
intracellular signaling by binding to receptors (Jiang 2011). During embryonic 
development the synthesis of hyaluronan is essential (Camenisch 2000, Tien 
2005) and constantly renewable tissues such as skin epidermis produce high 
levels of hyaluronan (Tammi 1994). On the other hand, hyaluronan levels 
increase in many cancers and inflammatory diseases (Jiang 2011, Tammi 
2008). Elevated hyaluronan levels indicate poor prognosis in many cancer 
types (Tammi 2008), while in chronic inflammatory diseases like rheumatoid 
arthritis, hyaluronan causes joint stiffness, pain and probably maintains 
inflammation (Naor 2003). Thus, hyaluronan is beneficial in promoting 
normal tissue regeneration, but in pathological cases it would be useful to 
control excessive hyaluronan synthesis.  
The regulation of hyaluronan synthases (HAS) has been studied widely at 
transcriptional level, and lately also post-translational modifications have 
been revealed. HAS transcription is controlled by transcription factors such as 
retinoid acid receptor (RAR), nuclear factor κB (NFκB), cAMP response 
element binding protein 1 (CREB1), signal transducer and activator of 
transcription  (STAT), specificity proteins 1 (SP1) and 3 (SP3), and often 
associates with growth factor and cytokine triggered signaling pathways 
(Jiang 2011, Pasonen-Seppänen 2003, Karvinen 2003, Saavalainen 2005). HAS 
enzymes are normally active only when localized in plasma membrane (Rilla 
2005) and post-translational modifications such as glycosylation, 
phosphorylation and ubiqitination control enzyme activation (Vigetti 2011, 
Karousou 2010, Vigetti 2009).  
The precursor sugars for hyaluronan synthesis - UDP-GlcNAc and UDP-
GlcUA - have received less attention as factors that could determine the rate 
of hyaluronan production. Hyaluronan synthesis depends on the 
concentration of intracellular UDP-GlcUA and is inhibited when the UDP-
GlcUA level is decreased by siRNA specific for UDP-glucose-6-
dehydrogenase (UGDH), or 4-MU (Vigetti 2006, Kultti 2009). Conversely, an 
elevated UDP-GlcUA level caused, by overexpression of UGDH, increases 
hyaluronan synthesis (Vigetti 2006). The present study focused on the other 
precursor – UDP-GlcNAc – and shows that both UDP-sugars are equally 
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important to hyaluronan production, and that a lack of UDP-GlcNAc inhibits, 
whereas an overdose stimulates hyaluronan production. Interestingly, UDP-
GlcNAc also dampens its own stimulation of hyaluronan synthesis by 
downregulating HAS2 mRNA. 
Hyaluronan has multiple roles in inflammation. A special form of hyaluronan 
coat, called cables, binds leukocytes and platelets onto cells of inflamed 
tissues (De la Motte 2003, De La Motte 1999). In inflammatory sites 
hyaluronan is digested to short fragments by platelet derived HYAL2 and 
reactive oxygen species, for example (Al-Assaf 2006, De la Motte 2009). The 
short hyaluronan fragments activate and maintain inflammation by inducing 
cytokine secretion and regulating leukocyte functions (Jiang 2011). 
Hyaluronan cables and their leukocyte binding have been studied in many 
cell types including fibroblasts, smooth muscle cells, mesangial cells, kidney 
epithelial cells and endothelial cells (De La Motte 1999, Evanko 2009, Vigetti 
2010, Wang 2004, Selbi 2006) following their induction by proinflammatory 
cytokines, viral infection, ER-stress and hyperglycemic conditions (De La 
Motte 1999, Wang 2004, Majors 2003, Shi 2006). This study shows that 
epidermal keratinocytes also produce hyaluronan cables and bind monocytes 
when treated with cytokines, hyperglycemia, and tunicamycin. The results 
also show that hyaluronan-mediated inflammatory responses, such as the 
cable-dependent monocyte binding, can be inhibited by depletion of 
intracellular UDP-GlcNAc using mannose, an inhibitor of hyaluronan 
synthesis discovered in this study. 
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2 Review of the literature 
2.1 THE HYALURONAN MOLECULE 
Hyaluronan is a large glycosaminoglycan, which consists of repeating 
disaccharide units of N-acetyl glucosamine (GlcNAc) and glucuronic acid 
(GlcUA) (figure 1). Hyaluronan synthesis takes place in the plasma 
membrane and the growing chain is simultaneously extruded into the 
extracellular space, allowing the synthesis of very long polymers, typically in 
the range of 104 disaccharides (~3.7 x 106 Da). At physiological pH the 
carboxyl groups on the GlcUA residues are negatively charged, making 
hyaluronan highly hydrophilic. The anionic nature, spatial restrictions 
around the glycosidic bond, and the weak and transient intramolecular 
hydrogen bonds determine the physico-chemical properties of hyaluronan. 
Unlike other glycosaminoglycans, hyaluronan is not built on a core protein 
and does not contain sulfate groups (Jiang 2011, Toole 2004, Hascall 2000). 
 
 
 
Figure 1. Chemical structure of the hyaluronan chain with its N-
Acetylglucosamine and Glucuronic acid repeating units, linked via alternating β1,4 
and β1,3 glycosidic bonds. 
2.2 UDP-SUGARS 
2.2.1 Synthesis  
Hyaluronan synthesis requires activated precursors in the form of the 
nucleotide sugars, UDP-GlcUA and UDP-GlcNAc. UDP-glucose-6-
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dehydrogenase (UGDH) synthesizes UDP-GlcUA directly from UDP-Glc. 
UDP-Glc is produced when glucose is first converted to glucose-6-P by 
hexokinase and then converted into glucose-1-P by phosphoglucomutase. 
Finally, the reaction of glucose-1-P with UTP forms UDP-Glc (figure 2). UDP-
GlcNAc is the end product of the hexosamine biosynthesis pathway. Since it 
is estimated that about 2% of the total intracellular glucose goes to 
hexosamine biosynthesis, this pathway can act as a cellular glucose sensor 
and control cellular energy metabolism. The pathway begins with the 
formation of glucosamine-6-P from fructose-6-P by glutamine fructose-6-
phosphate amidotransferase (GFAT). This is considered to be the rate-
limiting step of HBP (Marshall 1991). Glucosamine-6-P is then N-acetylated 
via an acetyl-CoA-mediated reaction and isomerizes to N-acetylglucosamine-
1-P. Finally, a reaction with UTP forms UDP-GlcNAc (figure 2). With a high 
supply of NH3, glucosamine-6-phosphate deaminase (GPI) may also convert 
fructose-6-P into glucosamine-6-P although this enzyme is believed to mainly 
function in the reverse direction (Varki 2008).  
Both GlcUA and GlcNAc can also be salvaged from glycoconjugates 
degraded by cells. Specific N-acetylhexosamine, sialic acid and glucuronic 
acid carriers export salvaged sugars from lysosomes for reuse. As much as 80 
% of N-acetylglucosamine on glycoproteins can be converted into UDP-
GlcNAc after degradation in liver lysosomes (Aronson 1983). UDP-GlcNAc 
can be converted into UDP-GalNAc by UDP-galactose 4-epimerase, resulting 
in an equilibrium between UDP-GlcNAc/UDP-GalNAc in a ~3:1 ratio. The 
common pool of UDP-GlcNAc and UDP-GalNAc is called UDP-HexNAc 
(Varki 2008). 
 
 
Figure 2. Main metabolic pathways related to the UDP-sugar precursors of 
hyaluronan. 
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2.2.2 Functions  
UDP-GlcUA and UDP-GlcNAc are transported to the Golgi where they are 
used as building blocks for glycoproteins, proteoglycans and glycolipids. 
UDP-sugar concentrations are ~20-fold higher in the ER/Golgi than in the 
cytosol (Hirschberg 1998). Golgi transporters have high affinity to UDP-
sugars (Km 1-10 mM) and it has been shown that overexpression of UDP-
GlcNAc transporter increases cellular release of UDP-GlcNAc, probably in 
vesicles together with secreted glycoconjugates, reflecting their content in the 
Golgi (Sesma 2009). 
UDP-GlcUA can also be used in the glucuronidation reactions of xenobiotic 
metabolism. For instance, glucuronic acid coupling to bile acids and 
xenobiotic compounds in the liver increases their solubility, and facilitates 
secretion (Varki 2008). 
UDP-GlcNAc is involved in intracellular signaling as a substrate for O-
GlcNAc transferase (OGT). OGT catalyzes the addition of O-GlcNAc to serine 
or threonine residues of many nucleocytoplasmic proteins. Dynamic O-
GlcNAc modification regulates protein activation, degradation and 
localization. The main function of O-GlcNAcylation appears to be the 
modulation of cellular processes in response to nutrients and stress. Crosstalk 
between O-GlcNAcylation and phosphorylation is extensive, and many 
proteins are reciprocally modified under different conditions at the same site 
by either O-GlcNAc or phosphate. O-GlcNAcylation and phosphorylation 
also dynamically modify the enzymes controlling each other’s cycling. 
Phosphatases are associated with the OGT, indicating that the same protein 
complexes can both remove phosphate and add an O-GlcNAc residue to 
some proteins (Hart 2011). O-GlcNAcylation is highly abundant on 
chromatin-associated proteins, e.g. histones (Hart 2011) and transcription 
factors such as SP1 and YY1 (Özcan 2010). 
2.2.3 Regulation of UDP-sugar pools 
The content of UDP-sugars is likely to be very tightly controlled. UDP-
HexNAc concentration varies between tissues and changes during aging 
(Fulop 2008). UDP-sugar pools have been manipulated by regulating the key 
enzymes of their synthesis or by controlling the availability of the synthesis 
precursors. The content of UDP-GlcUA has been decreased by using siRNA 
to block UGDH activity and increased by overexpression of UGDH. UDP-
GlcUA concentration can also be decreased by 4-MU, an excellent substrate of 
glucuronidation which consumes large amounts of UDP-GlcUA (Vigetti 2009, 
Kultti 2009, Vigetti 2006). UDP-GlcNAc content can be upregulated by 
overexpression of GFAT (Schleicher 2000), or treatment with glucosamine 
(Marshall 2005) or ammonium chloride (Ryll 1994).  
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2.3 HYALURONAN SYNTHASES 
2.3.1 HAS enzymes 
The mammalian HAS genes (HAS 1-3) are highly homologous. They are 
located in chromosomes 19, 8 and 16. HAS is a multispan transmembrane 
protein, including at least 6 transmembrane domains and 1-2 membrane-
associated domains. Hyaluronan synthesis occurs on the inner surface of the 
plasma membrane and the growing chain is extruded through the membrane 
into the extracellular space (Prehm 1984). HAS enzymes have dual catalytic 
activities, i.e. for the transfer of GlcNAc and GlcUA units from the 
corresponding nucleotide sugars. In vitro, in membrane preparations 
containing HAS enzymes need the precursor sugars and Mg2+ or Mn2+ to 
synthesize hyaluronan (Weigel 2007). The monosaccharides are added to the 
reducing end of the hyaluronan chain (Weigel 2007). HAS enzymes seem to 
have 3-14 times higher affinity to UDP-GlcUA (Km: 190 µM) than to UDP-
GlcNAc (Km: 400 µM) (Pummill 2002), whereas UDP-GlcNAc has 2-17 times 
higher cellular concentration than UDP-GlcUA.  
2.3.2 Transcriptional regulation of HAS 
The three HAS genes with divergent loci in the genome provide versatile 
transcriptional regulation. All HAS genes have distinct promoter regions and 
each isoenzyme can be differentially controlled by specific cellular signaling 
cascades. HAS1 seems to have the highest respective promoter activity and 
HAS2 the lowest, making HAS2 a more potent target for regulation than the 
other HAS isoforms (Monslow 2003). The expression of HAS genes is 
typically regulated in parallel (Kultti 2009, Vigetti 2009b, Pasonen-Seppänen 
2003, Karvinen 2003), but in some cases divergent regulation has also been 
reported. For example, progesterone reduces Has1 and Has2 expression in 
mouse uterine fibroblasts whereas Has3 expression is induced (Uchiyama 
2005). Also, TGF-β treatment upregulates HAS1 expression in human 
synoviocytes but inhibits HAS3 expression (Stuhlmeier 2004). 
Several transcription factors have been reported to regulate HAS gene 
expression. The most studied is the promoter of HAS2, which has been shown 
to contain functional response elements for different transcription factors 
including retinoid acid receptor (RAR), nuclear factor κB (NFκB), cAMP 
response element binding protein 1 (CREB1), signal transducer and activator 
of transcription (STAT), SP1 and SP3, and several cofactors that take part in 
regulation (Saavalainen 2005, Saavalainen 2007, Makkonen 2009, Monslow 
2006). In epidermal keratinocytes, epidermal growth factor (EGF) and retinoic 
acid induce HAS2 transcription: EGF receptor activation by EGF elicites 
binding of phosphorylated STAT3 to the HAS2 promoter, whereas retinoic 
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acid induces binding of RAR, retinoid X receptor (RXR), mediator protein 
(MED), CREB binding protein (CBP), SP1 and RNA polymerase II in to the 
HAS2 promoter (Saavalainen 2005). 
HAS genes also have alternative splicing which may influence enzyme 
activation or localization. A HAS1 splice variant has been detected in bladder 
cancer (Golshani 2007), multiple myeloma (Adamia 2003) and Waldenström’s 
macroglobulinemia (Adamia 2005). HAS3 has 3 splice variants, variant 1 and 
3 encode an identical protein and variant 2 has a different C-terminus (Gene-
database, NCBI). 
2.3.3 HAS and embryonic development 
During mouse development, HAS2 is expressed throughout all embryonic 
stages while HAS1 expression disappears after embryonic day 8.5, and HAS3 
is expressed later, particularly during the development of sensory organs. 
HAS2 is the only isoform highly expressed between embryonic days 8.5 and 
9.5, a time period of heart valve development. This is why HAS2 knockout 
mice die from several cardiovascular defects at embryonic day 9.5-10, while 
HAS1 and HAS3 knockouts show no obvious phenotypes (Camenisch 2000, 
Tien 2005). 
2.3.4 Comparison of HAS isoenzymes 
Even though the HAS isoenzymes are highly homologous there are some 
known differences between their properties. The affinity of HAS1 to its 
substrates is lower than that of HAS2, and HAS3 has the highest affinity.  It 
has been reported that HAS1 produces a significantly smaller pericellular 
hyaluronan coat than HAS2 and HAS3 (Itano 1999). Different HAS isoforms 
have also been reported to produce hyaluronan of different size, but there is 
some ambiguity in this property. Plasma membrane preparations of COS-1 
cells transfected with HAS3 produced smaller hyaluronan (1x105-1x106 Da) 
than corresponding HAS1 and HAS2 (2x105-2x106 Da) (Itano 1999). On the 
other hand, Brinck et al. (1999) found that CHO cell membrane preparations 
with transfected HAS2 produced large hyaluronan (3.9x106 Da), while HAS3 
and HAS1 synthesized relatively shorter molecules (0.12-1.0x106 Da and 
0.12x106 Da, respectively). In live CHO cells all isoforms produced 
hyaluronan larger than 3.9 x 106 Da (Itano 1999, Brinck 1999), and in live 
aortic smooth muscle cells HAS1 and HAS2 produced high molecular weight 
hyaluronan (2-10x106 Da), while HAS3 produced much lower molecular 
weight (~2x106 Da) (Wilkinson 2006). These partly inconsistent results suggest 
that the size of hyaluronan is not dependent only on HAS isoform. Obviously 
some post-translational and cell type specific modifications of HAS protein or 
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its environment also regulate the chain length of newly synthesized 
hyaluronan. 
2.3.5 Regulation of HAS enzymatic activity 
The enzymatic activity of HAS has been suggested to require plasma 
membrane localization, and be regulated by post-translational modifications 
and interactions with other membrane components. Inhibition of hyaluronan 
synthesis by 4-MU is associated with the disappearance of HAS from the 
plasma membrane (Rilla 2005). Intracellular domains of HASs contain 
potential phosphorylation sites and phosphorylation induces HAS activity 
(Vigetti 2011, Bourguignon 2007, Anggiansah 2003, Goentzel 2006, Ohno 
2001). It has also been shown that HAS2 is ubiquitinated on Lys190, and 
mutation of this residue leads to inactivation of the enzyme (Karousou 2010). 
The microenvironment is important to HAS activity. In bacterial cells HAS 
activity depends on cardiolipin (Weigel 2006). Mammalian cells do not 
contain cardiolipin in plasma membrane, but cholesterol might have a role in 
the regulation of HAS activity (Sakr 2008). 
A recent report also shows that HAS2 can form homodimers, and 
heterodimers with HAS3 (Karousou 2010). This offers even more ways to 
regulate HAS activity and hyaluronan synthesis. 
2.4 HYALURONIDASES 
In most tissues hyaluronan turnover is very rapid. The half-life of hyaluronan 
in blood is just a few minutes, in the dermal connective tissue about 2-3 days 
and in the epidermis 12 hours, while in the vitreous body and cartilage the 
half-life can be several weeks (Tammi 1991, Morales 1988, Fraser 1997). 
Enzymes called hyaluronidases on cell surface and lysosomes cooperate with 
exoglycosidases in the degradation of hyaluronan chains. Human cells 
express hyaluronidase (Hyal) genes, which include two sets of three 
contiguous genes located on two chromosomes. The cluster on chromosome 
3p21.3, - containing Hyal 1-3 - are the most important in hyaluronan 
catabolism.  The genes in chromosome 7q31.3 - Hyal4, Hyalp1 and Spam1 - 
make no major contribution to hyaluronan degradation in somatic tissues 
(Jiang 2011, Varki 2008).  
According to our current understanding, hyaluronan catabolism involves 
hyaluronan binding to a specific cell-surface receptor such as CD44, LYVE-1 
and HARE, which then internalize hyaluronan for lysosomal catabolism. 
Uptake may be facilitated by fragmentation of high molecular weight 
hyaluronan by the membrane-associated, glycosylphosphatidylinisotol-
anchored Hyal2 hyaluronidase. The fragments are taken into vesicles and 
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eventually enter lysosomes for complete degradation to monosaccharides, 
probably by Hyal1 and two exoglycosidases, β-glucuronidase and β-N-
acetylglucosaminidase (Stern 2003). Reactive oxygen species or free radicals 
can also cleave hyaluronan, especially during inflammation. Free radicals 
have been reported to enhance hyaluronan turnover (Al-Assaf 2006, Ågren 
1997). 
2.5 HYALADHERINS 
2.5.1 Properties and classification of hyaladherins 
Proteins able to interact with hyaluronan are called hyaladherins or 
hyaluronan binding proteins. Hyaladherins containing one or two 
hyaluronan binding domains (so called, link modules) belong to the 
hyaluronan and proteoglycan link protein gene family (HAPLN) (Day 2002). 
HAPLN can be divided into two subgroups, cell-surface receptors CD44, 
LYVE-1, HARE, STABILIN-1, and secreted HAPLNs such as aggrecan, 
versican, brevican, neurocan, and TSG-6. Hyaladherins without link modules, 
e.g. RHAMM, interact with hyaluronan via a specific, spatially ordered set of 
clustered basic amino acids (Day 2002). 
2.5.2 Cell-surface receptors 
The human CD44 gene, located in chromosome 11, produces in most cell 
types a transcript that creates the standard isoform, comprising exons 1-5 and 
16-20. Epithelial and endothelial cells, activated lymphocytes, and some 
malignant cells also express splice variants containing variable sets of 
additional exons between exons 5 and 16. The outermost N-terminal 
extracellular domain in exons 1-5 includes one hyaluronan binding link 
module. The variant exons bring in different extensions between the 
hyaluronan binding region and the standard C-terminus with plasma 
membrane and cytoplasmic domains (exons 16-20) (Isacke 2002). Additional 
variation occurs in the length of the cytoplasmic domain (Knudson 2002), 
while the transmembrane domain is highly conserved. CD44 is heavily 
modified post-translationally by N- and O-glycosylation, xylose-linked 
GAGs, sulphation, phosphorylation and acylation. A part of CD44 associates 
with cholesterol-rich microdomains called lipid rafts, and cholesterol 
depletion enhances CD44 shedding and inhibits its activation (Murai 2010). 
CD44 anchors hyaluronan on the plasma membrane (Tammi 1998), which can 
lead to hyaluronan internalization (Knudson 2002). Phosphorylation of CD44 
following hyaluronan binding activates intracellular signaling molecules and 
regulates CD44 interaction with the actin cytoskeleton through ERM (Ezrin, 
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Radixin and Moesin) (Legg 2002). CD44 forms complexes with matrix 
metalloproteinases (MMP) and with the ErbB group of growth factor 
receptors (Kim 2008). It can modulate several receptor tyrosine kinase 
activities and anchor an active form of MMP to cell surfaces (Yu 1999). 
Hyaluronan binding can induce CD44 clustering and thus activate CD44-
associated signals (Liu 1998). Through all these mechanisms CD44-
hyaluronan interaction can induce leukocyte rolling on endothelium 
(DeGrendele 1996), cell migration (Bourguignon 2001, Turley 2002), invasion 
(Bourguignon 2010, Zhang 2002), proliferation (Bourguignon 2001, Meran 
2011), differentiation (Bourguignon 2006) and chemotaxis (McKee 1996).  
The LYVE-1 hyaluronan receptor was found to be highly homologous with 
CD44, and the hyaluronan binding link module of LYVE-1 especially is 
almost identical with that of CD44. While CD44 is ubiquitously expressed in 
hematopoietic cells, fibroblasts and epithelial cells, LYVE-1 expression is 
quite unusual, mostly limited to lymphatic endothelium. LYVE-1 binds 
hyaluronan, but its role in hyaluronan endocytosis is still unclear (Jackson 
2004). 
The hyaluronan receptor HARE, also known as Stabilin-2, in expressed in 
liver, spleen and lymph nodes. It has an important role in systemic 
hyaluronan clearance. Two active isoforms have been found in tissues (Zhou 
2003). Cells stably transfected with full-length HARE create the other isoform 
when a minor subset of the receptor is proteolytically cleaved (Harris 2007). 
  
2.5.3 Aggregating hyaladherins 
Aggrecan, versican, neurocan and brevican are members of the hyalectin gene 
family. They have specific tissue distribution patterns, aggrecan being most 
prominent in cartilage, neurocan and brevican in the central nervous tissue 
and versican in soft connective tissues. Chondroitin sulphates of variable size, 
number and structure are attached to these core proteins, the N-terminals of 
which bind to a hyaluronan chain via two link modules. The binding to 
hyaluronan is stabilized by a link protein. Large aggregates are formed in 
ECM when multiple hyalectins are bound to a hyaluronan chain (Buckwalter 
1982, Sommarin 1983, Kiani 2002). 
2.5.4 TSG-6 and IαI 
TSG-6 is encoded by the TNFAIP6-gene in chromosome 2. Its size is 35 kDa 
and it contains one hyaluronan binding link module. TSG-6 is not 
constitutively present in healthy adult tissues, but its expression is induced 
during inflammation and ovulation. IαI is primarily a serum macromolecule, 
synthesized by hepatocytes in the liver. It consists of three polypeptides: a 16 
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kDa bikunin and two HCs ~83 kDa each. TSG-6 secreted into ECM can 
catalyze the transfer of HC from IαI into a covalent complex with hyaluronan. 
HC binding changes the mechanical and cell-binding properties of 
hyaluronan. TSG-6 - IαI complex can also modulate the protease network and 
thus inhibit inflammation (Milner 2003).  Furthermore, it was shown recently 
that binding to hyaluronan changes the conformation of TSG-6, leading to its 
dimerization, and that these dimers can form a non-covalent crosslink 
between hyaluronan chains (Baranova 2011). 
2.5.5 RHAMM  
The human RHAMM gene located in chromosome 5 produces alternatively 
spliced proteins. RHAMM localizes to cell surfaces, cytosol and the nucleus in 
most tissue types. It binds to hyaluronan via special types of binding motifs, 
which differ from HAPLNs (Yang 1994). RHAMM interaction with 
hyaluronan initiates several signaling cascades (Turley 2002). RHAMM 
appears to be involved in cellular motility and migration due its interactions 
with the cytoskeleton (Hall 1995). RHAMM-type hyaluronan binding motifs 
have also been found in a special matrix protein called Spacrcan, which binds 
hyaluronan in the interphotoreceptor matrix of the eye (Chen 2004).  
2.5.6 Non-classified hyaladherins 
Layilin with no link module or sequence homology to previously known 
hyaluronan receptors has been reported to bind hyaluronan (Bono 2001). 
Layilin has a role in cell migration and is found in microvilli, filopodia, 
lamellipodia and membrane ruffles (Bono 2001). It has also been reported that 
short hyaluronan fragments can interact with TLR 4, and induce secretion of 
inflammatory cytokines (Campo 2010). 
2.6 BIOLOGICAL FUNCTIONS OF HYALURONAN 
For a long time hyaluronan was thought to be just a space filler in tissues 
but several more specific roles have been discovered. The hydrophilic 
hyaluronan together with hyaladherins such as aggrecan, versican, TSG-6 
and IαI can form extracellular ”goo” (Toole 2000), which, for example in 
cartilage, makes a critical contribution to the maintenance of ECM 
viscoelasticy and osmotic pressure (Varki 2008). Hyaluronan is also an ideal 
lubricant in the joint. It can act as a scavenger of free radicals. Hyaluronan 
coat around the cell clears way for cell migration and proliferation. A special 
shape of hyaluronan coat (’cables’) can immobilize leukocytes in the tissue. 
Hyaluronan interactions with cell surface receptors such as CD44 and 
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RHAMM are known to be important activators for many cellular functions. 
Thus hyaluronan has multiple roles in early development, tissue 
organization, cell proliferation and differentiation. 
It can be said that hyaluronan is the initiator of new life. Hyaluronan-based 
matrix induces extrusion of the oocyte at ovulation and regulates the 
penetration of spermatozoa into an oocyte (Varki 2008). During embryonic 
development hyaluronan is abundant in tissues and especially prominent in 
sites of cell migration, such as the pathways for cell migration from neural 
crest, and in the developing cardiovascular system. In HAS2 knockout mice 
the absence of hyaluronan inhibits migration from heart tube endothelium to 
underlying mesenchyme, resulting in defective heart valves and embryonic 
lethality (Camenisch 2000). 
Skin epidermis is a good example of a tissue where hyaluronan may have a 
marked effect on homeostasis. In the human epidermis hyaluronan is the 
main component of ECM, which is found between all vital cell layers, but not 
in the terminally differentiated keratinocytes of the stratum corneum (Tammi 
1994). In basal and spinous layers of epidermis hyaluronan may assist 
keratinocyte proliferation and migration and therefore increase stratification. 
Hyaluronan in the stratum granulosum and stratum corneum may prevent 
the normally tight cell-cell contacts, and the organization of intercellular 
lipids, compromising the permeability barrier (Tammi 1998). Hyaluronan 
synthesis in the upper layers of the epidermis, induced by retinoic acid, EGF 
or KGF, weakens the adhesion between keratinocytes and leads to incomplete 
differentiation (Tammi 1988, Pasonen-Seppänen 2003, Karvinen 2003, 
Pasonen-Seppänen 2008). On the other hand, removal of hyaluronan from 
epidermis enhances the expression of differentiation-related proteins (Maytin 
2004, Passi 2004). 
2.7 HYALURONAN METABOLISM DURING INFLAMMATION 
Hyaluronan has multiple roles in inflammation. In acute inflammation 
several cytokines stimulate hyaluronan synthesis and induce hyaluronan coat 
transformation into cables (Table 1). Elevated hyaluronan levels and cables 
attract and bind platelets and leukocytes into the area of inflammation (De la 
Motte 2003, De la Motte 2009, Vigetti 2010). Hyal2 and reactive oxygen 
species mediate hyaluronan fragmentation into short oligosaccharides (figure 
3) (De la Motte 2009, Al-Assaf 2006, Soltes 2006), which then interact with 
TLR2, TLR4 and CD44, and induce cytokine expression (Table 2) (figure 3). In 
the later phase of inflammation hyaluronan assists in tissue remodeling by 
inducing cell migration and proliferation. Short hyaluronan fragments 
enhance angiogenesis by stimulating MMP activation and endothelial cell 
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migration (Isacke 2002, Deed 1997, Yu 2000) (figure 3). Elevated hyaluronan 
synthesis is often seen in chronic inflammation, and a high serum level of 
hyaluronan in patients with septic conditions is a sign of poor prognosis 
(Laurent 1996). In the chronic inflammation of rheumatoid arthritis, 
accumulation of free hyaluronan around synovial joints causes swelling, 
immobility and stiffness (Naor 2003). 
 
 
Figure 3. Hyaluronan metabolism in inflammation. Inflammation, viral infection, 
ER-stress and hyperglycemic conditions stimulate recasting of cell surface 
hyaluronan into cable-like structures. Hyaluronan cables attract and bind 
leukocytes and platelets. Platelet-derived Hyal2 or reactive oxygen species from 
leukocytes digest hyaluronan into shorter fragments. Hyaluronan fragments 
stimulate cell surface receptors such as CD44 and TLR4 and induce inflammatory 
reactions in host cells (De la Motte 2009) 
2.8 HYALURONAN INTERACTION WITH LEUKOCYTES 
Hyaluronan interacts in multiple ways with different leukocytes. 
Intraepithelial γδT-lymphocytes respond quickly to self-antigens released 
from damaged cells, and after activation they increase their own hyaluronan 
synthesis and stimulate that of the neighboring epithelial cells. Elevated 
hyaluronan levels attract macrophages into the injury site (Jameson 2005). 
Activated circulating T-lymphocytes gain the capacity to bind hyaluronan by 
expressing an active splice variant of CD44 with V6 and V9 exons (Bollyky 
2007). Hyaluronan interaction with CD44 enhances the transepithelial 
migration of leukocytes (Khan 2004), activates T- and B-lymphocytes (Bollyky 
2007, DeGrendele 1996, DeGrendele 1997, Lefebvre 2010, Maeshima 2011, Rafi 
1997), prolong neutrophil survival (Esnault 2003), and induces eosinophil 
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cytokine secretion (Ohkawara 2000). The interaction of hyaluronan with 
leukocytes is size dependent. HMW hyaluronan suppresses whereas LMW 
activates T-cell actions (Bollyky 2007). Only LMW hyaluronan causes 
prolonged neutrophil survival, and no effects are seen with HMW 
hyaluronan (Ohkawara 2000).  
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Table 1: Inflammatory agents which regulate hyaluronan synthesis. (↑) indicates 
upregulation and (↓) downregulation of hyaluronan synthesis. The form of cell surface 
hyaluronan is indicated as follows: HA-cables = cable-type hyaluronan coat, (-) no 
hyaluronan cables, n.s. = not studied. 
 
Agent Cell/ Tissue HA Form of 
hyaluronan 
Reference 
EGF keratinocyte, primary skin 
fibroblast, oral mucosa 
fibroblast 
↑ - (Pasonen-Seppänen 2003, 
Yamada 2004) 
IFN-γ keratinocyte, lung fibroblast ↑ - (Sampson 1992, Sayo 
2002) 
IGF fibroblast, mesothelial cell ↑ n.s. (Honda 1991, Kuroda 
2001) 
IL-1β skin fibroblast, oral mucosa 
fibroblast, synoviocyte from 
rheumatoid arthritis, fetal 
skin fibroblast, vascular 
endothelial cell 
↑ HA-cables (Yamada 2004, Vigetti 
2010, Oguchi 2004, 
Kennedy 2000) 
IL-4 synovial membrane ↑ n.s. (Hyc 2009) 
IL-6 skin fibroblast ↑ n.s. (Duncan 1991) 
IL-15 vascular endothelial cell ↑ n.s. (Estess 1999) 
KGF keratinocyte ↑ n.s. (Karvinen 2003) 
PDGF fibroblast, mesothelial cell, 
vascular endothelial cell, 
vascular SMC 
↑ n.s. (Heldin 1992, Heldin 1989, 
Evanko 2001, Jacobson 
2000, Suzuki 2003) 
PolyI:
C 
primary mucosa SMC, lung 
fibroblast 
↑  - HA-cables (Evanko 2009, de la Motte 
2003) 
TGF-β keratinocyte, synoviocyte ↓ n.s. (Pasonen-Seppänen 2003, 
Sayo 2002, Kawakami 
1998) 
TGF-β synoviocyte from 
rheumatoid arthritis, 
fibroblast, keratinocyte, 
vascular endothelial cell 
↑ n.s. (Oguchi 2004, Heldin 1989, 
Suzuki 2003, Sugiyama 
1998) 
TNF-α fetal skin fibroblast, lung 
fibroblast, vascular 
endothelial cell, synovial 
membrane 
↑ HA-cables (Sampson 1992, Vigetti 
2010, Kennedy 2000, Hyc 
2009) 
TNF-β vascular endothelial cell ↑ HA-cables (Vigetti 2010) 
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Table 2: Inflammatory agents upregulated by hyaluronan. HMW > 1000 kDa, LMW < 1000 
kDa, Mix= hyaluronan size not defined. 
 
Inflammatory 
agent 
Cell/ Tissue Form 
of HA 
Receptor Reference 
Ccl2/ MCP-1 renal tubular 
epithelial cell, 
peripheral blood 
mononuclear cell, 
macrophage 
LMW TLR4, 
CD44 
(Yamawaki 2009, McKee 
1996, Beck-Schimmer 
1998) 
Ccl3/ MIP-1α monocyte Mix  (Wallet 2010) 
Ccl3/ MIP-1α macrophage LMW CD44 (McKee 1996) 
Ccl3/ MIP-1α macrophage LMW TLR2, 
TLR4 
(Scheibner 2006) 
Ccl4/ MIP-1β macrophage, cumulus 
cell 
LMW TLR2, 
TLR4 
(Jiang 2005, Shimada 
2008) 
Ccl4/ MIP-1β macrophage LMW CD44 (McKee 1996) 
Ccl4/ MIP-1β monocyte Mix  (Wallet 2010) 
Ccl5 / Rantes macrophage, cumulus 
cell 
LMW CD44, 
TLR4, 
TLR2 
(McKee 1996, Shimada 
2008) 
CSF1/ M-CSF dermal epithelial cell LMW  (Taylor 2004) 
CSF2/ GM-
CSF 
monocyte, eosinophil Mix, 
LMW 
 (Wallet 2010, Esnault 
2003) 
Cxcl1/KC endothelial cell, 
macrophage 
LMW CD44 (McKee 1996, Takahashi 
2005) 
Cxcl1/KC bronchoalveolar 
lavage fluid 
LMW Non-TLR4 (Zhao 2010) 
Cxcl2/ MIP-2α macrophage LMW  (Bai 2005) 
Cxcl9/MIG macrophage LMW  (Horton 1998) 
Cxcl10/ crg-
2/IP-10 
macrophage, 
monocyte 
LMW CD44 (McKee 1996, Wallet 
2010, Horton 1998) 
I-CAM epithelial cell, 
eosinophil 
LMW  (Taylor 2004, Ohkawara 
2000) 
IFN-γ T-lymphocyte LMW  (Blass 2001) 
IGF-1 macrophage LMW CD44 (Noble 1993) 
IL-1α monocyte Mix  (Wallet 2010) 
IL-1β monocyte Mix  (Wallet 2010) 
IL-1β bronchoalveolar 
lavage fluid 
LMW Non-TLR4 (Zhao 2010) 
IL-1β dendritic cell, 
chondrocyte 
LMW 
 
TLR4, 
CD44 
(Campo 2010b, Termeer 
2000) 
IL-6 bronchoalveolar 
lavage fluid 
LMW Non-TLR4 (Zhao 2010) 
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IL-6 chondrocyte, peripheral 
blood mononuclear cell, 
monocyte, B-lymphocyte, 
cumulus cell 
LMW, 
MIX 
TLR4, 
TLR2, 
CD44 
(Yamawaki 2009, 
Wallet 2010, Shimada 
2008, Campo 2010b, 
Iwata 2009) 
IL-8 melanoma cell, dermal 
endothelial cell, 
macrophage, monocyte 
LMW TLR4, 
CD44, 
MD-2 
(McKee 1996, Taylor 
2004, Taylor 2007, 
Voelcker 2008) 
IL-10 fibroblast-like synoviocyte, 
monocyte, serum, T-
lymphocyte, B-lymphocyte 
HMW, 
MIX 
 (Wallet 2010, Iwata 
2009, Huang 2011, 
Asari 2010, Bollyky 
2007) 
IL-12 macrophage, dendritic cell LMW CD44 (Termeer 2000, Hodge-
Dufour 1997) 
IL-
12p40 
monocyte Mix  (Wallet 2010) 
MIP-2 bronchoalveolar lavage fluid LMW Non-TLR4 (Zhao 2010) 
MIP-2 macrophage, dermal 
endothelial cell, monocyte 
LMW TLR4, 
CD44, 
MD-2 
(Taylor 2004, Taylor 
2007, Zheng 2009) 
MME macrophage LMW  (Horton 1999) 
MMP-2 melanoma cell LMW TLR4 (Voelcker 2008) 
MMP-3 macrophage Mix  (Taylor 2007) 
MMP-9 dendritic cell LMW Non-
CD44 
non-
RHAMM, 
non-TLR4 
(Fieber 2004) 
MMP-10 dermal microvascular 
endothelial cell 
LMW  (Taylor 2004) 
MMP-12 macrophage LMW  (Horton 1999) 
MMP-13 dendritic cell LMW Non-
CD44 
non-
RHAMM, 
non-TLR4 
(Fieber 2004) 
MyD88 chondrocyte LMW TLR4 (Campo 2010a) 
PAI-1 macrophage LMW  (Horton 2000) 
Socs3 macrophage Mix  (Taylor 2007) 
TGF-β eosinophil, B-lymphocyte LMW, 
MIX 
CD44, 
TLR4 
(Ohkawara 2000, Iwata 
2009) 
TGF-β2 monocyte Mix CD44, 
MD-2, 
TLR4 
(Taylor 2007) 
TIMP-1 fibroblast-like synoviocyte HMW  (Huang 2011) 
TIMP-2 fibroblast-like synoviocyte HMW  (Huang 2011) 
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TNF monocyte Mix  (Wallet 2010) 
TNF-α bronchoalveolar lavage fluid LMW Non-TLR4 (Zhao 2010) 
TNF-α dendritic cell, 
chondrocyte, macrophage, 
B-lymphocyte 
LMW, 
Mix 
TLR4, 
CD44 
(Campo 2010b, Iwata 
2009, Zheng 2009, 
Termeer 2002) 
TRAF-6 chondrocyte LMW TLR4 (Campo 2010a) 
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Table 3: Inflammatory agents downregulated by hyaluronan. HMW > 1000 kDa, LMW < 
1000 kDa, Mix= size not defined. 
 
Inflammatory 
agent 
Cell/ Tissue Form of 
HA 
Receptor Reference 
A2ar macrophage LMW CD44 (Collins 2011) 
Cox-2 synovial fibroblast HMW CD44 (Mitsui 2008) 
IL-1β fibroblast-like 
synoviocyte 
HMW CD44 (Mitsui 2008, Huang 2011) 
IL-6 corneal epithelial 
cell, synovial 
fibroblast 
HMW CD44 (Mitsui 2008, Pauloin 
2009) 
IL-8 corneal epithelial 
cell, fibroblast-like 
synoviocyte 
HMW CD44 (Pauloin 2009, Wang 
2006) 
MCP-5 serum HMW  (Asari 2010) 
MIP-2 serum HMW  (Asari 2010) 
MMP-1 chondrocyte HMW CD44 (Hashizume 2010) 
MMP-1 synovial fibroblast LMW, 
HMW 
CD44 (Shimizu 2003) 
MMP-3 chondrocyte, 
fibroblast-like 
synoviocyte 
HMW CD44 (Huang 2011, Hashizume 
2010) 
MMP-13 chondrocyte HMW CD44 (Hashizume 2010) 
PGE(2) macrophage HMW CD44 (Yasuda 2010) 
p-selectin serum HMW  (Asari 2010) 
Rantes serum HMW  (Asari 2010) 
SCF serum HMW  (Asari 2010) 
Socs7 macrophage Mix  (Taylor 2007) 
TNF-α fibroblast-like 
synoviocyte 
HMW CD44 (Mitsui 2008, Huang 2011) 
uPA macrophage LMW  (Horton 2000) 
VEGF serum HMW  (Asari 2010) 
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2.9 HYALURONAN CABLES 
A special form of hyaluronan coat, called hyaluronan cables, appears in 
inflammation, ER-stress, hyperglycemic conditions, α1-adrenergic receptor 
stimulation, viral infection or mimic of viral infection by double-stranded 
RNA (polyinosinic:polycytidylic acid=Poly I:C) (De La Motte 1999, Majors 
2003, Shi 2006, Wang 2004). Cells respond to these stress factors by reshaping 
their hyaluronan coat, and long hyaluronan cables appear in the extracellular 
space. The cables attract and bind leukocytes and platelets (De La Motte 1999, 
De la Motte 2009). In vitro, IL-1β− and TNFα-treatments induce hyaluronan 
cables (Vigetti 2010). TNFα induces cable formation in endothelial and 
epithelial cell cultures but not in smooth muscle cells (SMC). IFNα,β and γ are 
incapable of stimulating hyaluronan-dependent monocyte binding in SMC 
cultures (De La Motte 1999, Vigetti 2010).  In vivo, similar hyaluronan 
structures are present in the intestine of patients with inflammatory bowel 
disease (Kessler 2008). In vitro, hyaluronan cables have also been found in 
fibroblasts and mesangial cells (De La Motte 1999, Wang 2004, Vigetti 2010, 
Evanko 2009, Selbi 2006a).  
Hyaluronan cables span long distances, combine hyaluronan produced by 
several cells and anchor to the cells by HAS2 and/or CD44 (Vigetti 2010). The 
formation of cables does not require intact cytoskeleton or membrane 
protrusions (Evanko 2009). It has been suggested that some kind of 
hyaluronan chain cross-linking exists in the cables. However, there seems to 
be a lot of variation in the structure and composition of hyaluronan cables 
present in different cell types.  In tissue sections from inflammatory bowel 
disease hyaluronan colocalizes with IαI and versican (De la Motte 2003). Also 
in cultured human primary colon mucosal SMC and immortalized human 
proximal tubular epithelial cells hyaluronan cables contain IαI and versican, 
which are hyaladherins that may cross-link hyaluronan chains (De la Motte 
2003, Selbi 2006b). TSG-6 remains the only documented enzyme capable of 
the covalent transfer of IαI-derived HCs to hyaluronan, but hyaluronan cable 
formation can take place without TSG-6 (Selbi 2006b). In murine and human 
airway SMC cultures, no IαI and versican is detectable in hyaluronan cables 
(Lauer 2009). The formation of the hyaluronan cables does not require de novo 
protein synthesis and they can be built up in a serum-free medium (De la 
Motte 2003). Poly I:C stimulates hyaluronan cable formation in a STAT1- and 
PI3K/Akt-dependent, but TLR3-independent manner (Bandyopadhyay 2010). 
In summary, the molecular structure and origin of hyaluronan cables are still 
unclear. 
Monocytes bind to hyaluronan cables via their CD44 receptors (De La 
Motte 1999). Platelets also bind to cables, and the membrane bound Hyal2 on 
the surface of platelets can mediate hyaluronan fragmentation (figure 3) (De 
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la Motte 2009). Hyaluronan cables obscure cell surface adhesion molecules, 
such as intracellular adhesion molecule (ICAM), and therefore inhibit 
signaling through this receptor (Zhang 2005). 
2.10 HYALURONAN FRAGMENTS 
Hyaluronan plays different structural and signaling roles depending on its 
molecular size. Newly synthesized hyaluronan generally exists as a HMW 
polymer (>1000 kDa), but in many pathological conditions hyaluronan 
becomes more polydisperse and LMW fragments have been reported. HMW 
hyaluronan is thought to be anti-inflammatory whereas its fragments 
stimulate inflammation by inducing the expression of inflammatory 
cytokines (Table 2) and by regulating leukocyte functions (Jiang 2011). 
Hyaluronan fragmentation might be due to dysregulation of HAS and Hyal 
enzymes. Also reactive oxygen species released during tissue injury can cause 
fragmentation (Al-Assaf 2006, Soltes 2006). In lung injury, extracellular 
superoxide dismutase can inhibit inflammation by preventing oxidative 
fragmentation of hyaluronan (Gao 2008). Hyaluronan fragments can induce 
CD44 cleavage, resulting in signals different from those of HMW hyaluronan 
(Sugahara 2003) (Table 2 and 3).  
2.11 TISSUE REMODELING 
Because hyaluronan can induce cell migration and proliferation, it is 
important in tissue repair. Hyaluronan accumulates in tissues that undergo 
rapid remodeling due to injury, cancer or inflammation (Tammi 2009, Toole 
2002). High hyaluronan content in the matrix opens the way for migrating 
cells, induces detachment of the cells, and amplifies growth factor signals 
(Jiang 2011). After skin wounding hyaluronan accumulates transiently in the 
granulation tissue and epidermis (Tammi 2005). In epidermis hyaluronan 
enhances proliferation and retards differentiation in a pool of migration-
competent keratinocytes, which rapidly cover the wound area and re-
establish the permeability barrier (Tammi 2009). Hyaluronan also upregulate 
dermal fibroblast proliferation (Röck 2010) and in granulation tissue 
hyaluronan stimulates the expression of many cytokines (Table 3), and short 
hyaluronan fragments induce angiogenesis by stimulating endothelial cell 
proliferation through the hyaluronan receptors CD44 and RHAMM (Jiang 
2011). CD44 also provides a cell surface docking receptor for MMP9, the 
proteolytic activity of which induces angiogenesis and tissue remodeling (Yu 
1999). 
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3 Aims of the study 
The aim in this thesis was to study the mechanisms and signals that regulate 
hyaluronan synthesis, including the expression and activity of HAS enzymes, 
and the organization of the hyaluronan coat on cell surfaces. The main focus 
was in the hyaluronan precursor sugars - UDP-GlcUA and UDP-GlcNAc - 
because the role of UDP-GlcNAc in particular had received little attention 
previously.  
 
Considering the surge of hyaluronan metabolism in wound healing, 
inflammation, and cancer, the work was also motivated by opportunities to 
find new therapeutic targets in the processes that control hyaluronan 
synthesis. In particular, two issues were considered important: 
1. Analyzing cellular UDP-GlcNAc content as a regulator of hyaluronan 
synthesis.  
2. Studying the formation of cell surface hyaluronan cables and their 
influence on monocyte binding.  
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4 Materials and Methods 
4.1 MATERIALS 
The cells used in this project are shown in Table 4. When studying UDP-
sugars and hyaluronan synthesis, cells were incubated for 2 hours to 5 days 
with 1-20 mM mannose, fructose, and galactose, 0-25 mM glucose, 0.25-6 mM 
glucosamine, and 0.2 mM 4-MU (all from Sigma). Hyaluronan cable 
expression was induced by adding recombinant IL-1β and TNF-α (Biosource, 
Camarillo, CA, USA) at 10 ng/ml, and tunicamycin (Streptomyces, from 
Sigma) at 2.5 µg/ml.   
 
Table 4: Cell lines used in the project. Culture conditions for each are presented in the 
original publications. 
Origin of cells 
Name of 
cells 
Original 
publication Reference 
Newborn rat skin 
keratinocytes 
REK I, IV and V (Baden 1983) 
Human epidermal 
keratinocytes 
HaCaT II (Boukamp 1988) 
African green monkey 
kidney  
COS-1 III (Gluzman 1981) 
Monocytes from a human 
histiocytic lymphoma 
U937 IV and V Dr. Carol de la Motte, Lerner 
Res. Inst., Cleveland, OH, USA 
Human mesothelium LP-9,  
 
III Dept. Pathol., Kuopio Univ. 
Human cutaneus 
fibroblasts 
Skin 
fibroblast 
III Dr. Reidar Grenman, Turku 
Univ. 
Human fibroblast from 
cutaneus tumor stroma 
Tumor 
fibroblast 
III Dr. Reidar Grenman, Turku 
Univ. 
Human diploid lung 
fibroblast 
WI-38 III (Hayflick 1961) 
Human chondrosarcoma  HCS III (Takigawa 1989) 
Human breast 
adenocarcinoma  
MCF-7 III (Soule 1973) 
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4.2 METHODS 
The methods used in this thesis are listed in Tables 5-8. Specific details of 
every method are presented in the original publications (I-V). Table 5 itemizes 
the methods used to study the content of hyaluronan. The UDP-sugar 
analysis methods are presented in Table 6. Table 7 shows the methods used to 
study the expression and function of genes and proteins. Table 8 shows the 
methods used to study cell and tissue functions. 
Table 5: Methods used to study hyaluronan. Specific details are presented in the original 
publications. 
Purpose Method 
Original 
publication Reference 
Content of 
hyaluronan  
Enzyme –linked sorbent 
assay for hyaluronan 
I,II, III, IV 
and V 
(Hiltunen 2002) 
Quantity of newly 
synthesized 
glycosaminoglycans 
Metabolic labeling with 
[35S]SO4 and 
[3H]glucosamine 
I (Tammi 2000) 
Demonstration of 
hyaluronan in fixed 
cell cultures 
Staining with biotinylated 
Hyaluronan Binding 
Complex (bHABC) for 
light- and fluorescence 
microscopy 
I, III, IV and 
V 
(Tammi 1998) 
Demonstration of 
hyaluronan coat on 
live cells 
Incubation with 
fluorescently labeled 
HABC for confocal 
microscopy 
III and V (Rilla 2008) 
Quantitation of 
hyaluronan in 
granulation tissue 
Stainings tissue sections 
with bHABC and 
densitometry with 
Microtek® scanner 
V Method optimised 
by Jukka 
Kuokkanen and 
Mika Hyttinen, 
Univ. Kuopio 
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Table 6: Methods used to quantify UDP-sugars. Specific details are presented in original 
publications I-III. 
Purpose Method 
Original 
publication Reference 
Content of  
UDP-sugars 
ion pairing HPLC-
MS/MS 
I Method optimised by Marjo 
Jauhiainen and Dr. Seppo 
Auriola, Univ. Kuopio 
Content of  
UDP-sugars 
anion-exchange 
HPLC 
II, III Method optimized from: 
(Tomiya 2001) 
 
Table 7: Methods used to study genes and proteins. Specific details are presented in the 
original publications. 
Purpose Method 
Original 
publication Reference 
Gene transcription 
(HAS1,2,3; CD44; 
YY1; SP1; GFAT1,2; 
UGDH) 
Quantitative PCR II, III, IV  
YY1- and SP1-gene 
silencing 
Transient siRNA 
transfection 
II  
HAS-overexpression Transient HAS- 
pDendra2-C 
transfection 
III HAS- pDendra2-C- 
constructs made by 
Dr. Juha Hyttinen, 
Univ. Kuopio 
Protein biosynthesis Metabolic labeling with  
L-[35S]methionine  
I  
YY1 and SP1 protein 
expression 
Western blot II  
YY1 and SP1 
substitution with O-
GlcNAc  
Immunoprecipitation 
and western blot 
II  
Transcription factor 
binding sites in 
HAS2 promoter 
In silico promoter 
analysis 
II (http://mordor.cgb.ki.s
e/cgi-
bin/CONSITE/consite/) 
Transcription factor 
binding to HAS2 
promoter (YY1, SP1, 
Ncor, CBP and PCAF) 
Chromatin 
immunoprecipitation 
II  
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Table 8: Methods used to study cell and tissue functions. Specific details are presented in 
the original publications. 
Purpose Method 
Original 
publication Reference 
Keratinocyte 
migration 
Scratch wound-assay in 
monocyte cultures 
I (Pienimäki 2001) 
Keratinocyte 
proliferation 
Cell counting with a 
hemocytometer 
I (Rilla 2004) 
Hyaluronan 
dependent 
monocyte binding 
to keratinocytes 
Counting of monocytes 
attached to keratinocyte 
cultures before and after 
hyaluronidase treatment 
IV, V Optimised from (De 
la Motte 1999) 
Formation of 
granulation tissue 
Rat wound healing model 
with subcutaneous sponge 
implant 
V (Kössi 1999) 
Number of 
leukocytes in 
granulation tissue 
Rat wound healing model 
with subcutaneous sponge 
implant 
V (Kössi 1999) 
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5 Results 
5.1 REGULATION OF HYALURONAN SYNTHESIS BY UDP-
SUGAR SUPPLY 
5.1.1 Regulation of intracellular UDP-sugar pools 
The intracellular pool of UDP-HexNAc was increased by glucosamine, 
whereas mannose and GFAT1-siRNA treatments reduced it (I, II, III).  To 
reduce the pool of UDP-GlcUA, 4-MU treatment was used (I).  The contents 
of UDP-sugars show up to 50-fold differences between cell types (III Fig. 8). 
Cells of mesenchymal origin generally contained higher amounts of UDP-
HexNAc and UDP-GlcUA, compared with epithelial cells (III Fig. 8). The 
magnitude of the UDP-GlcNAc increase following glucosamine treatment 
also varied between rat keratinocytes (REK), human keratinocytes (HaCat) 
and monkey kidney cells (COS-1) (I, II, III).  
 
5.1.1.1 Glucosamine 
A dose-dependent increase in UDP-HexNAc content was detected following 
the addition of glucosamine at 0.1-6.0 mM final concentrations in the growth 
medium, although close to maximum effect was reached already with 1 mM 
concentration (II Fig. 2B). In REK and COS-1 cultures 2 mM glucosamine 
caused a more than 11-fold increase in the UDP-HexNAc pool (I, Fig. 4A and 
III, Fig. 2A) and in the HaCaT culture 6 mM glucosamine increased it x 9-fold 
(II, Fig. 2B). Analysis of different time points after the introduction of 
glucosamine (6 mM) indicated that already at 2 hours the size of the UDP-
HexNAc pool had increase 2.5-fold, and remained elevated at 24 hours. 
Glucosamine also caused a 6-fold increase in UDP-GlcUA, but this response 
emerged later, and was detectable only 6 hours after the introduction of 
glucosamine (I Fig. 4A, II Fig. 1). This study shows that both UDP-HexNAc 
and UDP-GlcUA pools can be elevated by glucosamine (I, II, III). 
5.1.1.2 Mannose 
Mannose decreased the UDP-HexNAc pool size in a dose-dependent way.  A 
significant, 20% reduction in the intracellular UDP-HexNAc content was seen 
already with 5 mM mannose, while 20 mM mannose caused the maximal, 
~50% downregulation in the pool size (I, Fig. 3A, II, Fig. 2A). The effect of 
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mannose was rapid and a reduction of UDP-HexNAc was seen already after 
30 minutes (I, Fig. 3B), and the low levels were still detected after 24 hours (I, 
Fig. 4A), but in HaCaT cells the UDP-HexNAc content was normalized to 
control level after 24 h incubation with mannose (II, Fig. 1A). Mannose was 
found to increase the intracellular UDP-GlcUA content. In REK cells, 2 h 
incubation with mannose caused a 25% increase in UDP-GlcUA content (I, 
Fig. 3), whereas in HaCaT cells the upregulation was over 50% (II, Fig. 1B).  
When REKs were treated simultaneously with mannose and glucosamine, 
glucosamine dominated the response and the UDP-HexNAc pool was 
increased 8.5-fold (I, Fig. 4A). In summary, mannose depleted the level of 
UDP-HexNAc and elevated the level of UDP-GlcUA (I, II). 
5.1.1.3 4-MU 
4-MU decreased both UDP-HexNAc and UDP-GlcUA (I). The response was 
most potent after 2 h incubation, but was still evident after 12 h. With 0.2 mM 
4-MU a 60% decrease in the UDP-GlcUA pool and a 20% decrease in the 
UDP-HexNAc pool were noted, while with a 1 mM dose the UDP-GlcUA 
content was reduced by 85% and UDP-HexNAc content by 40%. Combined 
with mannose (10 mM), 0.25 mM 4-MU caused about the same response in 
UDP-sugar contents as mannose or 4-MU alone, UDP-HexNAc levels being 
reduced by 35% and UDP-GlcUA content by 50% (I Fig. 5). This study 
demostrated that the depletions of the UDP-sugar pools by 4-MU and 
mannose are not additive (I). 
5.1.1.4 Gfat1-siRNA 
GFAT1 is one of the key enzymes of the hexosamine biosynthesis pathway, 
which ends in UDP-GlcNAc (figure 2). By siRNA-silencing of GFAT1 for 48h, 
UDP-HexNAc levels were reduced by ~30% (II, Fig. 4A). The result confirmed 
that GFAT1 makes a significant contribution to the maintenance of the 
cellular UDP-HexNAc level (II). 
5.1.2 Changes in the UDP-sugar pool sizes are reflected in hyaluronan 
synthesis 
Cellular concentrations of UDP-HexNAc and UDP-GlcUA were closely 
correlated with hyaluronan synthesis (figure 4A) (III). Changes in UDP-sugar 
contents were rapidly reflected on hyaluronan synthesis (figure 4B) (I, II).  In 
addition, comparison of different cell lines showed that their basal 
hyaluronan synthesis was highly correlated with the precursor sugar 
contents. Glucosamine, mannose, GFAT1-siRNA and 4-MU which all caused 
changes in UDP-HexNAc and UDP-GlcUA contents, also regulated 
hyaluronan synthesis (figure 4B and I, II, III, V).  
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The hyaluronan synthesis rate and the content of UDP-sugars were studied in 
seven cell lines (III). Cells were cultured close to confluence in standard 
culture conditions to reach a steady state, past the most active phase of 
proliferation. Up to 50-fold differences were found in the content of UDP-
GlcNAc and UDP-GlcUA between the cell lines, and, interestingly, 
hyaluronan synthesis was found to correlate with the content of precursor 
sugars. The content of the two UDP-sugars also correlated with each other.  
The stimulatory effect of glucosamine on hyaluronan synthesis was 
significant already with 0.25 mM glucosamine, and in HaCaT cells the 
maximum (1.5-fold) effect was obtained with 1 mM concentration (II, Fig. 
2D). In REK cultures a somewhat higher, 2.5-fold increase in hyaluronan 
synthesis was seen with 2 mM glucosamine (I, Fig. 4B).  In contrast to 
glucosamine, mannose dose-dependently inhibited hyaluronan synthesis. 
With 5 mM mannose a ~25% inhibition was noted, and with 20 mM 
concentration hyaluronan synthesis was decreased by ~55% (I, Fig. 1B, II, Fig. 
2C).  The inhibition induced by mannose was rapid; a 2h incubation with 20 
mM mannose decreased hyaluronan levels by 50% (I Fig. 2A), and inhibition 
was still significant (~55%) after 24 h (I, Fig. 1B, II, Fig. 2C).  When cells were 
treated simultaneously with mannose and glucosamine, hyaluronan synthesis 
increased 2.5-fold, as much as with glucosamine alone (I, Fig. 4B). Treating 
cells with 20 mM glucose, galactose and fructose did not markedly influence 
hyaluronan synthesis (I, Fig. 1A).  The synthesis rates of sulfated GAGs, 
chondroitin and heparan sulphates, analyzed in REK cultures using 
metabolic labeling, were less sensitive to mannose than hyaluronan. A 
decrease in chondroitin sulphates was not seen until 10 h after adding 20 mM 
mannose (I, Fig. 2B).  
4-MU (0.2 mM) significantly inhibited hyaluronan synthesis (-40%) after 6 
h incubation in REK cells (I, Fig. 5). A combined treatment with mannose and 
4-MU caused as strong inhibition as mannose or 4-MU alone, 4-MU being 
slightly a more potent inhibitor at the 6 h time point whereas mannose was 
slightly more efficient at 24 h, then resulting in 35% inhibition (I, Fig. 5E,F). 
To summarise these data, glucosamine increases the intracellular pool of 
UDP-HexNAc and stimulates hyaluronan synthesis, whereas mannose 
reduces the UDP-HexNAc level and 4-MU UDP-GlcUA level, and both 
inhibit hyaluronan synthesis (I, II, III, V).  
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Figure 4. Interrelationship between hyaluronan synthesis and cellular UDP-sugar 
contents. (A) Hyaluronan synthesis, UDP-HexNAc and UDP-GlcUA contents in 
different cell lines are presented as % of those in mesothelial (LP-9) cells (100 
%). (B) Hyaluronan synthesis and UDP-sugar levels after glucosamine, mannose, 
GFAT1-siRNA and 4-MU treatments. REK-cultures were incubated for 6 h with 
0.25 mM 4-MU. HaCaT cells were incubated for 6 h with 6 mM glucosamine, 20 
mM mannose, or transfected with GFAT1-siRNA (48 h after transfection). The 
results are presented as % of non-treated cultures. (C) HAS1-3 expressions 
correlated with UDP-HexNAc. mRNA expressions were studied in the cell lines 
named in panel A and correlated with the content of intracellular UDP-HexNAc. 
(D) HAS2 mRNA and UDP-HexNAc contents after glucosamine, mannose and 
GFAT1-siRNA treatments. mRNA and UDP-HexNAc levels were analysed in 
HaCaTs incubated for 0-24 h with mannose (20 mM) and glucosamine (6 mM), or 
for 48h with GFAT1-siRNA (white and black diamonds). All HAS mRNA levels were 
related to that of the ARPO gene. 
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5.2 UDP-HEXNAC CONTROL OF HAS EXPRESSION 
The expression of HAS genes was also studied when cells were treated with 
mannose and glucosamine. Interestingly, HAS2 expression was induced 
when the UDP-HexNAc pool was reduced with mannose or GFAT1-siRNA 
while the glucosamine-induced increase of the UDP-HexNAc pool was 
associated with decreased HAS2 expression (II). All three HAS isoforms were 
regulated by glucosamine and mannose (figure 5A,B). Human keratinocytes 
(HaCaT) and rat keratinocytes (REK) responded in a slightly different time 
scale, in REKs glucosamine treatment caused Has2 downregulation already 
after 2h incubation (figure 5B) whereas in HaCaTs glucosamine first 
upregulated HAS2 expression and the downregulation was not seen until 
after 6h incubation (figure 4D and II, Fig. 3). Has1 and Has3 mRNA levels 
were also studied in REK cells. Glucosamine after 2 and 6h incubations did 
not remarkably change Has1 expression but 24h incubation caused about 50% 
inhibition (figure 5B). Conversely, mannose upregulated Has1 at all three 
time points (2h, 6h, and 24h), with the most potent effect occurring at 6h, 
when the increase was almost 2.5-fold (figure 5A). Two-hour and 6h 
incubations with glucosamine inhibited Has3 expression more than 50%, but, 
unexpectedly, 24h incubation caused a 3-fold upregulation (figure 5B). A 24h 
incubation with mannose upregulated Has3 expression 2-fold, whereas no 
effect was found in shorter time points (figure 5A).  
 
5.2.1 Regulation of HAS2 expression 
Because HAS2 is the dominant isoform in HaCaT cells, its regulation was 
studied in more detail (II). In HaCaTs, glucosamine regulated HAS2 
expression in a time-dependent manner. A 2h incubation with glucosamine 
caused a 2.4-fold induction of HAS2 expression, while after 6 h and 24 h 
incubations its expression was significantly downregulated (-50%). Mannose 
slightly induced HAS2 expression already after 2 h incubation; a 2-fold 
upregulation was seen after 6 h and inhibition continued at 24 h (II fig. 3). 
Like mannose, GFAT1-siRNA caused a significant upregulation (~1.5-fold) of 
HAS2 expression (II fig. 4B). Glucosamine reduced HAS2 expression in a 
dose-dependent manner, 2 mM glucosamine caused a ~30% decrease while 20 
mM inhibited HAS2 expression by 70% (figure 5C). With the 6 mM dose of 
glucosamine the amount of HAS2 enzyme probably became the limiting 
factor of hyaluronan synthesis, explaining why 2 mM glucosamine stimulated 
hyaluronan synthesis more effectively than 6 mM (II, Fig. 2D).  
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Figure 5. Time-dependent regulation of Has expression by mannose and 
glucosamine. REKs were incubated with 20 mM mannose (A) and 2 mM 
glucosamine (B), and mRNA levels of the Has isoforms were analyzed after 2, 6 
and 24 h. (C) Concentration dependence of Has2 expression in REKs incubated 
for 6 h with 0-20 mM glucosamine. All Has mRNA levels were related to that of 
ARPO. 
5.2.2 Effects of YY1 and SP1 on HAS2 expression 
The above results reveal a negative correlation between UDP-HexNAc 
content and HAS2 expression. To study the mechanism of this regulation in 
more detail, the binding of transcription factors to the HAS2 promoter was 
studied (II). The binding of CREB1, NF-κB and STAT3, transcription factors 
that have been previously verified to be functional in HAS2 promoter 
(Saavalainen 2005, Saavalainen 2007, Makkonen 2009, Monslow 2006), were 
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not influenced by mannose or glucosamine. In contrast, the transcription 
factors YY1 and SP1 showed altered binding to the HAS2 promoter after 
mannose and glucosamine treatments.  The binding of cofactors that can 
enhance and suppress transcription, such as CBP, NcoR1 and PCAF, were 
also studied. YY1 binding to the HAS2 promoter increased significantly after 
glucosamine treatment, and mannose decreased SP1 binding in region 8 and 
YY1 in region 1, suggesting that they are important for HAS2 expression (II, 
Fig. 6A, B). Coactivator-CBP binding to the HAS2-promoter was reduced, 
whereas corepressor-NcoR1 binding was increased, after glucosamine 
treatment. Binding of the coactivator PCAF to the promoter was increased 
after mannose treatment (II, Fig. 6A,B).  A schematic view of the recruitment 
of YY1, SP1, CBP, PCAF and NcoR1 after glucosamine and mannose 
treatments is shown in figure 6. The importance of YY1 and SP1 was further 
studied by using specific siRNAs, YY1 and SP1 knockdown caused 2.4–fold 
and 1.5-fold upregulation of HAS2 expression, respectively (II, Fig. 7).  So, 
glucosamine increased their binding to the promoter, leading to 
transcriptional downregulation, and when their binding was inhibited by 
mannose, transcription was upregulated. 
 
 
 
Figure 6. Recruitment of SP1 and YY1 and transcription co-factors after mannose 
and glucosamine treatments. HaCaTs were incubated for 6 h with 20 mM 
mannose and 6 mM glucosamine. Transcription factors bound to the proximal 
HAS2 promoter were analyzed with ChIP. 
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5.2.3 O-GlcNAc modification in YY1 and SP1 
YY1 and SP1 can both be modified by O-GlcNAc glycosylation (Özcan 2010). 
We studied whether glucosamine and mannose change the level of O-GlcNAc 
modification of these transcription factors (II, Fig. 8). Glucosamine 
significantly increased O-GlcNAc modification of YY1 1.6-fold and SP1 2.7-
fold, whereas mannose slightly decreased both (II, Fig. 8).  The results suggest 
that O-GlcNAc modification can regulate the binding of these transcription 
factors to the HAS2 promoter, and in that way regulate HAS2 expression, as a 
response to the changed intracellular content of UDP-HexNAc. 
5.3 UDP-SUGAR REQUIREMENTS OF DIFFERENT HAS 
ISOFORMS 
5.3.1 Substrate sensitivity of HAS1-3 
To study the differences in the hyaluronan synthetic capacity between the 
three HAS isoenzymes (III), COS-1 cells were transiently transfected with 
Dendra2-HAS1-3 constructs. COS-1 cells expressed low levels of endogenous 
HASs and synthesized very little hyaluronan (III, Fig. 1B). Interestingly, 
hyaluronan synthesis remained at a low level after HAS1 overexpression, 
whereas HAS2 and HAS3 overexpression significantly increased hyaluronan 
synthesis (III, Fig. 1B). Because HAS1 is known to have a lower in vitro 
affinity for precursor sugars than HAS2 and HAS3 (Itano 1999), the effect of 
increased UDP-sugar levels was studied by adding 2 mM glucosamine to the 
culture medium. The content of UDP-HeXNAc increased more than 10-fold 
and that of UDP-GlcUA ~3-fold (III, Fig. 2). The elevated UDP-sugar content 
caused by glucosamine was associated with a dose-dependent, up to 4-fold 
increase in the amount of hyaluronan synthesized in HAS1-transfected cells. 
In contrast, HAS2-transfected cells showed only a 1.6-fold increase, and no 
change in the hyaluronan synthesis rate was found in HAS3- transfected cells 
(III, Fig. 3). This suggests that the UDP-sugar concentrations needed by HAS1 
are markedly higher than those needed by HAS2 or HAS3. 
To confirm the differences in the hyaluronan synthesis rate between the 
HAS-isoenzymes, the cell surface coat formed by hyaluronan was analyzed in 
HAS-overexpressing cells. During the on-going synthesis the growing 
hyaluronan chain is still attached to the HAS enzyme, forming a hyaluronan 
coat, which can be visualized with fluorescently labeled HABC in live cells. 
This microscopic examination showed that HAS2- and HAS3-transfected cells 
had prominent hyaluronan coats (III, Fig. 4A). The coat present in HAS2–
transfected cells appeared larger and more diffuse than that on HAS3-
transfected cells (III, Fig. 4A). Glucosamine treatment did not change the size 
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of HAS2- and HAS3-induced coats. In contrast, cells transfected with HAS1 
and maintained in the basal medium showed no cell surface hyaluronan, 
while supplementation of the medium with 1 mM glucosamine resulted in 
the formation of intensely stained, large hyaluronan coats also on HAS1-
transfected cells (III, Fig. 4).  
The consumption of UDP-sugars, studied in HAS-transfected cells, caused 
a clear depletion of both UDP-GlcNAc and UDP-GlcUA, even when the 
medium was supplemented with 1 mM glucosamine. Again, the largest 
depletion was found in cells transfected by HAS3, a smaller decrease was 
noted with HAS2, but no significant changes were observed with HAS1 (III, 
Fig. 7).  
5.3.2 Effect of glucose on hyaluronan synthesis by HAS1-3 
As both hyaluronan precursor sugars are downstream metabolites of glucose, 
the effect of glucose concentration on hyaluronan synthesis was studied in 
HAS-transfected cultures (III). COS-1 cells are normally cultured with a 
medium, containings 25 mM glucose. When cells were transferred to a 
glucose-free medium, hyaluronan synthesis was significantly inhibited, even 
in HAS3-transfected cultures (III, Fig. 5). Raising glucose from 0 to 5 mM 
(physiological level), caused an increase in hyaluronan synthesis. However, 
increasing glucose concentration from 5 to 25 mM showed a less marked 
elevation in hyaluronan production with all HAS isoforms (III, Fig. 5D,E,F). 
Hyaluronan coats formed in the total absence of glucose (0 mM) were 
markedly smaller than those formed in the control medium, even in HAS2- 
and HAS3 -transfected cells. Their coat sizes were not changed when the 
glucose concentration was raised from 5 mM to 25 mM (III, Fig. 6). HAS1-
transfected cells did not produce hyaluronan coats at any glucose 
concentration tested (III, Fig. 6). 
5.3.3 Correlation of UDP-sugar contents with hyaluronan synthesis and 
different HAS isoforms 
The contents of UDP-GlcNAc and UDP-GlcUA, synthesis of hyaluronan, and 
expression of HAS-genes were studied in 7 different human cell lines (III). 
The UDP-sugars and the synthesis of hyaluronan were higher in the cells of 
mesodermal origin, i.e. in fibroblasts and mesothelial cells, while epithelial 
cells, such as keratinocytes and breast cancer cells contained generally lower 
UDP-precursor sugar concentrations and synthesized less hyaluronan (figure 
4A, III, Fig. 8). 
When the expression of HAS isoenzymes was studied in these 7 cell types, 
a strong, positive correlation was found between HAS1 expression and the 
level of both UDP-precursor sugars (R=0.978 for UDP-GlcNAc and R=0.997 
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for UDP-GlcUA). HAS2 expression also correlated with UDP-GlcNAc and 
UDP-GlcUA (R=0.892 and R=0.815), whereas no correlation between HAS3 
and UDP-sugars was found (figure 4C, III, Fig. 9). The mRNA levels of 
GFAT1, GFAT2, UGDH were measured on different cell lines to check 
whether a correlation exists between the expression of UDP-sugar 
synthesizing enzymes, UDP-sugar contents and hyaluronan synthesis. No 
correlations were found between the expression levels of GFAT1 or UGDH 
and UDP-sugars, but there was a tendency to a positive correlation between 
the expression of GFAT2 and UDP-GlcNAc (R=0.883) and UDP-GlcUA 
(R=0.883). The expression of UGDH, producing the UDP-GlcUA, was found 
to be high in cancer cell lines compared with non-malignant cells, but it did 
not correlate with the hyaluronan synthesis rate in these cell lines (III, Fig. 
10F). 
5.4 HYALURONAN IN INFLAMMATION 
Hyaluronan has been shown to have an important role in skin inflammation 
(Tammi 2009, Tammi 2005). In this study a new hyaluronan-mediated 
inflammatory change was revealed in cultured keratinocytes. Microscopic 
analysis showed that epidermal keratinocytes could form hyaluronan cables 
(figure 7) that bind monocytes in a hyaluronan-dependent manner (IV, V). 
Mannose, the novel inhibitor of hyaluronan synthesis inhibited this 
hyaluronan-dependent monocyte binding (V). In an in vivo wound model 
mannose also reduced hyaluronan, the formation of granulation tissue, and 
the number of leukocytes accumulated in the granulation tissue (V) (Kössi 
1999). Mannose also inhibited keratinocyte migration, and slightly slowed 
down cell proliferation (I).  
5.4.1 Hyaluronan cables in keratinocytes 
Previous studies have described a special form of hyaluronan coat called 
cables in many cell types (De La Motte 1999, Evanko 2009, Vigetti 2010, Wang 
2004, Selbi 2006). This study (IV) showed that epidermal keratinocytes can 
also form these cable-like structures when subjected to inflammatory stimuli 
such as IL-1β and TNFα, or to tunicamycin causing ER-stress, or to 
hyperglycemic conditions (20 mM Glucose) (IV, Fig.1).  The formation of 
hyaluronan cables did not require increased hyaluronan synthesis. 
Tunicamycin, IL-1β and TNFα actually decreased the content of hyaluronan 
in medium (IV, Fig. 3), tunicamycin and IL-1β also inhibited the expression of 
Has genes (IV, Fig.4). The microscopic structure of the cables was highly 
sensitive to the fixation. In live cells stained with fluorescently labeled HABC, 
the cables rose up above the cell layer as hair-like structures, whereas in fixed 
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cultures the “hair” collapsed into cables that fell down to form horizontal 
bundles of hyaluronan chains (figure 7, IV, Fig. 1, V, Fig. 3). The biological 
significance of these hyaluronan cables probably is in their capability to bind 
leukocytes into injured tissue. In this study we show that IL-1β and 
tunicamycin treated keratinocytes bind, in a hyaluronan dependent way, 
more monocytes than non-treated cultures (IV, Fig. 2, V, Fig. 4) 
 
 
Figure 7. Hyaluronan cables on keratinocytes. (A) Untreated REKs. (B) REKs 
incubated for 3 h with tunicamycin (2.5 µg/ml). Hyaluronan on cells fixed with 
Histochoice MB was visualized with bHABC. 
5.4.2 Inhibition of hyaluronan-dependent monocyte binding by mannose 
In the first phase of the project (I) I discovered the ability of mannose to 
inhibit hyaluronan synthesis. The effect of mannose on the formation of 
hyaluronan cables and hyaluronan-dependent binding of monocytes was 
later studied in keratinocytes treated with tunicamycin and IL-1β to induce 
cable formation (V). The results show that mannose inhibited these events. IL-
1β treatment doubled the number of monocytes bound to keratinocytes, and 
mannose significantly counteracted this effect (V, Fig. 4A). Mannose also 
inhibited tunicamycin-induced, hyaluronan-dependent binding of monocytes 
to keratinocytes (V, Fig. 4B). 
5.4.3 Inhibition of hyaluronan synthesis in granulation tissue by mannose 
It has been demonstrated that mannose injections inhibit the formation of 
granulation tissue in an in vivo wound-healing model (Kössi 1999). 
Importantly, the influx of leukocytes into the hollow sponge forming the 
matrix for subcutaneous granulation tissue was also significantly reduced by 
mannose, the numbers of neutrophils  particularly being significantly 
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decreased (-70%)  (V, Fig. 2C). The mannose isomers glucose, galactose and 
fructose had no such effects. Since Kössi et al. have shown that mannose 
reduces the amount of glycosaminoglycans in the granulation tissue, we 
wanted to see whether this applies to hyaluronan. For that purpose, we used 
paraffin sections from the experiments produced by Kössi et al., to study the 
amount of hyaluronan in the granulation tissue using histochemical staining 
with bHABC (V). Image analyses of the stainings showed that the intensity of 
the hyaluronan positive staining was reduced (-28%), and the depth of the 
hyaluronan positive area was decreased (-50%) in mannose treated sponges 
compared with control samples (V, Fig. 2A,B). To conclude, our data and 
those of Kössi et al. (1999) suggest that mannose decreased hyaluronan 
synthesis and leukocyte accumulation in vivo, leading to the granulation 
tissue growth block via reduced cell migration and proliferation. In line with 
this idea, we noticed in our experiments with keratinocyte cultures that 
mannose inhibited cell migration (-30%) (I, Fig. 6D), and also slightly reduced 
proliferation during a 5-day exposure (I, Fig. 6A,B). On the other hand, we 
noticed that while mannose and 4-MU inhibited hyaluronan synthesis to 
about the same extent (I, Fig. 5E,F), 4-MU (0.2 mM) was 4-fold more potent 
than mannose (10 mM) in the proliferation assay, suggesting that mannose 
may be less toxic to the cells. 
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6 Discussion 
6.1 UDP-SUGAR CONTENT, HYALURONAN SYNTHESIS AND 
HAS EXPRESSION 
6.1.1 Availability of precursors regulates hyaluronan synthesis 
The most widely studied factors regulating hyaluronan synthesis have been 
the HAS enzymes, and a lot of information has been obtained about the ways 
HAS transcription is regulated, but the influence of the precursor sugars has 
received less attention. The present study shows that the availability of  the 
precursor sugars UDP-GlcNAc and UDP-GlcUA regulate hyaluronan 
synthesis in several ways (figure 8). Whereas Kultti et al. (Kultti 2009) and 
Vigetti et al. (Vigetti 2009) have shown that 4-MU decreases UDP-GlcUA 
content, and inhibits hyaluronan synthesis, the present study shows that the 
contents of both precursor sugars are equally important to hyaluronan 
synthesis.  
The metabolism of UDP-sugars is an integral part of the cellular 
mechanism for sensing the supply of energy, particularly that of glucose. The 
synthesis of UDP-sugars responds to many exogenous and endogenous 
stimuli (Fulop 2008, Sweeney 1993, Wice 1985, Ryll 1994), and the dynamic 
changes in the content of UDP-sugars by these stimuli can also regulate the 
synthesis of hyaluronan. This study shows that incubation with glucosamine 
increases the intracellular content of UDP-GlcNAc and UDP-GlcUA, and 
induces hyaluronan synthesis, while incubation with mannose decreases 
UDP-GlcNAc content and inhibits hyaluronan synthesis. The UDP-GlcUA 
pool size can be decreased by 4-MU and this limits hyaluronan synthesis (I, II, 
III).  
Glucosamine is transported into the cells by glucose transporters (GLUT) 
simultaneously inhibiting glucose uptake (Hresko 1998). As different GLUTs 
have different affinities to glucosamine, the rate and kinetics of glucosamine 
uptake may depend on the combination and abundance of GLUTs expressed 
in a certain cell or tissue type (Uldry 2002). Glucosamine enters the 
hexosamine biosynthesis pathway in a step downstream of the rate-limiting 
GFAT enzymes and is converted into UDP-GlcNAc (Kim 1974, Marshall 
2005), as shown also in our results (I, II, III). The three cell lines (REK, HaCat 
and COS) only slightly differed from each other in their response to 
glucosamine, i.e. 6h incubation with 1 mM glucosamine elevated UDP-
HexNAc level 10-fold in HaCaT cells (II, Fig. 2B), and 9-fold in COS-1 cells 
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(III, Fig. 2A). At the same time, the UDP-GlcUA level was increased 2.25-fold 
in HaCaTs (data not shown) and 2.6-fold in COS-1 cells (III, Fig. 2B).  
Mannose can also be transported into cells via GLUTs but there are also 
mannose-specific transporters (Panneerselvam 1996). Intracellular mannose 
probably modulates the activity of glucosamine-6-phosphate isomerase (GPI), 
which can either deplete or increase glucosamine-6P, the precursor of UDP-
GlcNAc (Cayli 1999). The GPI1 and 2 and GFAT1 and 2 enzymes function in 
the same, rate-limiting step of hexosamine biosynthesis, and these enzymes 
can probably compensate for each other. This may explain why we see only a 
~50% reduction in UDP-GlcNAc content after Gfat1 siRNA or mannose 
treatments (I, II).  
4-MU has been shown to inhibit hyaluronan synthesis in vivo mouse model 
(Nagy 2010) and in vitro many cell types (Kultti 2009, Vigetti 2009, Kakizaki 
2004). It inhibits HAS expression and reduces the content of UDP-GlcUA 
(Kultti 2009), as shown also in this study (I). 4-MU is also a potent inhibitor of 
cell proliferation, migration and invasion (Kultti 2009). This study shows that 
4-MU markedly decreases the content of UDP-GlcUA also in keratinocytes, 
while its reducing effect on the UDP-HexNAc pool is smaller (I). 
Other glycosaminoglycans using the same precursors as hyaluronan were 
less sensitive to changes in the UDP-sugar pools. For example, chondroitin 
sulphate synthesis stays more active after the UDP-GlcNAc depletion caused 
by mannose (I). Hyaluronan is probably more sensitive to changes in 
precursors because it is the only glycosaminoglycan synthesized on the 
plasma membrane and HAS uses cytosolic precursor sugars. The enzymes 
responsible for the synthesis of other GAGs are located in the Golgi 
apparatus. UDP-sugars are actively transported to the ER/Golgi, where 
concentrations are 20-fold higher than in cytosol (Hirschberg 1998). 
6.1.2 UDP-GlcNAc content and HAS2 expression 
Interestingly, an intracellular signaling system regulated HAS expression 
when UDP-GlcNAc content was changed. Low UDP-GlcNAc content caused 
by mannose or GFAT1-siRNA induced HAS expression while the increased 
UDP-GlcNac pool induced by glucosamine was associated with 
downregulation of HAS expression (II). This signaling loop is probably meant 
to inhibit too radical shifts in the hyaluronan synthesis rate. 
UDP-GlcNAc is also a substrate for OGT, the enzyme catalyzing the 
addition of O-GlcNAc to proteins. Dynamic O-GlcNAc modification controls 
localization, activation and degradation of signaling proteins (Love 2005). 
Consequently, O-GlcNAc-mediated signaling might be a direct link between 
UDP-GlcNAc content and the regulation of HAS expression.  Our results 
showed that the transcription factors YY1 and SP1 bind to the HAS2 promoter 
and that their binding is controlled by changes in the UDP-GlcNAc content 
41 
 
caused by mannose or glucosamine (II). YY1 and SP1 are known to regulate 
several genes and they can act as activators or repressors of transcription, 
depending on the gene and associated cofactors, such as co-repressor NcoR1 
or co-activators CBP and PCAF. YY1 has a vital role in development (Gordon 
2006, Shi 1997) and SP1 contributes to insulin signaling and the development 
of metabolic syndrome (Solomon 2008).  Mannose reduced the binding of SP1 
to the HAS2 promoter, while glucosamine induced both SP1 and YY1 binding 
to the promoter (figure 6). SP1- and YY1-siRNA experiments showed that 
both of these transcription factors are repressors of HAS2 expression. 
Interestingly mannose and glucosamine also modulated post-translational 
modifications of SP1 and YY1, mannose reducing whereas glucosamine 
increasing the O-GlcNAc modification in SP1 and YY1 (II). It has been shown 
that hypoglycosylated SP1 is subject to proteasome degradation whereas 
glucosamine-induced hyperglycosylation increases SP1 protein stability (Han 
1997). O-GlcNAc modification also regulates the nuclear localization of SP1 
since insulin-induced SP1 glycosylation causes SP1 accumulation in the 
nucleus (Majumdar 2006). O-GlcNAc modification enhances YY1 binding to 
DNA, because it disturbs the association of YY1 with retinoblastoma protein, 
which inhibits YY1 binding to DNA (Hiromura 2003). These results support 
the hypothesis that mannose, by reducing O-GlcNAc modifications in YY1 
and SP1, causes reduced binding of SP1 to the HAS promoter, perhaps due to 
proteasomal degradation of SP1, and results in enhanced HAS2 expression. In 
contrast, glucosamine increases O-GlcNAc modifications in YY1 and SP1, 
supporting their binding to the promoter and resulting in downregulation of 
HAS2 expression (figure 8). This hypothesis may be simplified and the 
possibly independent roles of cofactors such as CBP, PCAF, and NcoR1 
remain unknown. For instance, increased O-GlcNAc levels are associated 
with upregulated expression of corepressor genes such as NCoR1 and SMRT 
(Bowe 2006). Nevertheless, the transcriptional regulation of HAS2 by the 
substrate of the same enzyme is interesting and probably important. 
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Figure 8. Schematic model of the interrelationship between hyaluronan synthesis 
and UDP-precursor sugars. The contents of the UDP-sugars, especially UDP-
GlcNAc controls hyaluronan synthesis by acting as a substrate for HAS, and 
simultaneously regulates HAS gene expression, probably by O-GlcNAc 
modification of the transcription factors YY1 and SP1. 
6.2 INTERRELATIONSHIPS BETWEEN UDP-SUGARS AND HAS 
ISOFORMS 
HAS isoforms are known to have different Km values for their precursor 
sugars which are probably reflected in their different affinities to these 
substrates. Itano et al. (Itano 1999) tested the different HAS isoenzymes with 
the precursor sugars using membrane fractions isolated from HAS-
transfected cells and found that HAS1 has the highest and HAS3 the lowest 
Km for the precursor sugars, especially UDP-GlcNAc. Our results with 
glucosamine-treated, HAS-transfected cells are in line with those findings. 
HAS1 needs high precursor concentrations to synthesize hyaluronan and to 
produce a notable hyaluronan coat, while HAS2 and HAS3 can effectively 
produce hyaluronan even when the UDP-sugar content is lower (III). These 
results suggest that active hyaluronan synthesis by HAS1 requires a high 
content of UDP-GlcNAc 
Glucose is the precursor of all UDP-sugars (figure 2). It is therefore quite 
natural that glucose starvation inhibits hyaluronan synthesis by 
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downregulating UDP-GlcNAc and UDP-GlcUA contents. However, raising 
glucose from physiological (5 mM) to hyperglycemic (25 mM) levels caused 
relatively small changes in hyaluronan synthesis during a 6 h incubation in 
COS-1 cultures (III). Different cell types may vary in their tolerance to 
hyperglycemic conditions, and maintaining the cells for more extended 
periods in high glucose medium may be necessary to show the differences in 
the ability to maintain stable hyaluronan synthesis between 5 mM and 25 mM 
glucose concentrations. We have shown that vascular smooth muscle cells 
cultured in 25 mM glucose over several cell passages synthesize significantly 
more hyaluronan than cells cultured in 5 mM glucose (Sainio 2010). In rat 
keratinocyte cultures, a short incubation with 25 mM glucose caused the 
formation of hyaluronan cables (IV), but did not change the amount of 
secreted hyaluronan (data not shown).  
Interestingly, the expression levels of HAS1 and HAS2 in different cell 
types correlated with precursor sugar contents. A particularly strong positive 
correlation occurred between the precursor sugars and HAS1, but the 
expression of HAS2 and the total hyaluronan synthesis were also clearly 
related to precursor sugar contents, unlike HAS3, which showed no 
correlation (III). Apparently, in a steady state situation cells balance HAS1 
and HAS2 expression in an economical level and express these only if there 
are enough precursor materials. HAS3 sustains hyaluronan synthesis even in 
low UDP-sugar contents, so it may not be necessary to balance its expression 
with the precursor contents. Studies on human mesangial and proximal 
tubular cells have shown that hyperglycemic conditions induce HAS2 
expression but do not influence HAS3 expression (Yevdokimova 2006, Jones 
2001). Microarray and PCR analyses of different cell types have shown 
significant overexpression of HAS2 in hyperglycemic conditions (Sainio 2010, 
Maier 2010, Rugheimer 2008). Evidently, the intrinsic UDP-sugar content 
correlates with HAS2 expression, and probably also with HAS1 expression. 
However, because of the relatively low expression level in many cell types, 
the analysis of HAS1 expression is difficult and not often performed. 
Expression levels of the enzymes producing hyaluronan precursor sugars 
were also studied in an attempt to explain the cell type-related differences in 
UDP-sugar levels, and correlated with hyaluronan synthesis. GFAT1 and 
GFAT2 are presumably the key enzymes in hexosamine biosynthesis 
producing UDP-GlcNAc, while UGDH is responsible for UDP-GlcUA 
synthesis (figure 2). A somewhat surprising finding was that there was no 
correlation between the mRNA levels of most of these enzymes and 
hyaluronan synthesis. A weak correlation was found between Gfat2 mRNA 
and hyaluronan (III). Gfat1 and 2 expression levels are known to be tissue 
specific, for instance Gfat1 is predominantly expressed in the liver and fat, 
whereas a high expression of Gfat2 is found in the brain (Oki 1999). 
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Furthermore, both Gfat1 and Gfat2 expression change during ageing (Fulop 
2008). Gfat1 expression is upregulated in muscle after an isocaloric-sucrose 
diet (Ferrer-Martinez 2006). There are fewer studies on the regulation of Gfat2 
expression, but during aging Gfat2 expression increases especially in the 
heart tissue and at the same time the content of UDP-HexNAc increases 
(Fulop 2008).  
Overexpression of UGDH or its suppression by siRNA correlate with 
increased and reduced hyaluronan synthesis, respectively (Vigetti 2006). 
Increased UGDH expression has been linked to prostate cancer and also 
correlated there with increased hyaluronan synthesis (Wei 2009). However, 
when we studied several normal and cancer cell lines we found that UGDH 
expression did not correlate with hyaluronan synthesis. Instead, UGDH 
expression was high in several cancer cell lines, regardless of the activity of 
hyaluronan synthesis (III). I hypothesize that this may be due to the 
important role of UGDH in the production of glucuronides (Varki 2008). 
Cancer cells can remove hormones, growth inhibitors and drugs by 
glucuronidation to neutralize their growth restricting activities. Androgen-
dependent prostate cancer cells have been shown to control their growth by 
using a UGDH–induced increase in the UDP-GlcUA supply for 
glucuronidation. At the same time, these cells synthesize very little 
hyaluronan, while the increased UGDH activity markedly contributes to the 
excretion of inactivated androgens (Wei 2009). 
6.3 HYALURONAN CABLES IN KERATINOCYTES 
Hyaluronan cable structures have been reported in many cell types (De la 
Motte 2003, De la Motte 2009a, Vigetti 2010), but not in skin cells (IV). 
Epidermal keratinocytes normally express a tight pericellular hyaluronan 
coat (Pienimäki 2001, Rilla 2004), but cytokines, ER-stress and hyperglycemic 
conditions induced the formation of these extended hyaluronan structures 
also in keratinocyte cultures (IV, Fig. 7). A special feature of the hyaluronan 
cables is their capability to bind leukocytes and platelets (De la Motte 2003, 
De la Motte 2009b). In this study, we show that non-stressed keratinocytes 
bind relatively low numbers of leukocytes, but binding can be doubled with 
IL-1β, TNFα or tunicamycin. Interestingly, the amount of secreted 
hyaluronan did not increase after these treatments (IV). In some cell types 
hyaluronan cable expression and upregulation of hyaluronan synthesis occur 
simultaneously (Selbi 2006b, Lauer 2009) but this was not the case in 
keratinocyte cultures. Overexpression of HAS3 (Selbi 2006b) stimulates, 
whereas overexpression of HAS2 inhibits cable formation in renal tubular 
epithelial cells (Selbi 2006a). The formation of cables in HAS-overexpressing 
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cells is obviously cell type specific and depends on factors other than total 
hyaluronan synthesis or specific HAS type, because in the studies of our 
group other cell lines overexpressing either HAS2 or HAS3 did not show 
cables (data not shown). Also, the present results showed no correlation 
between Has expression and hyaluronan cables because IL-1β and 
tunicamycin inhibited Has expression whereas TNFα induced it (IV). 
6.4 MANNOSE AS AN ANTI-INFLAMMATORY AGENT 
Mannose is a major component of many glycans. Its metabolic activation 
starts with the conversion to mannose 6-phosphate. Several in vitro and in 
vivo studies have reported the anti-inflammatory actions of mannose or 
mannose 6-phosphate. Mannose can reduce leukocyte attachment to venules 
(Stoolman 1983) and slow down their proliferation (Muchmore 1984). 
Mannose also inhibits the oxidative lysis of neutrophils (Rest 1988) and 
cytolysis mediated by natural killer cells (Werkmeister 1983). The effects of 
mannose have also been studied in an in vivo wound-healing model (Kössi 
1999). Results from that study show that mannose causes a significant 
reduction in the number of leukocytes in the wound fluid and retards the 
formation of granulation tissue.  Even orally administered mannose 6-
phosphate improved wound healing and had an anti-inflammatory influence 
in the mouse (Davis 1994). There is no all-inclusive explanation for why 
mannose has these anti-inflammatory influences. It has been proposed that 
mannose 6-phophate could displace from cell-surface receptors lysosomal 
enzymes, which are essential for leukocyte extravasations into the 
inflammatory site. The present results suggest that the anti-inflammatory 
actions of mannose are partially mediated by reduced hyaluronan synthesis 
(I, II, V). The results show that mannose is an effective hyaluronan synthesis 
inhibitor (I, II) and it also causes reduced hyaluronan levels in the granulation 
tissue in vivo (V). We also show that mannose can prevent hyaluronan-
dependent monocyte binding into cytokine-treated keratinocyte cultures (V) 
and that the treatment is not toxic to the cells (I). Previous studies on rats and 
mice have shown that mannose added to drinking water has no toxic side 
effects (Davis 2001, Alton 1998). In summary, mannose is a powerful 
hyaluronan synthesis inhibitor and it might have potential in drug 
development in cases where inordinate hyaluronan synthesis has to be 
modulated. 
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7 Summary and Conclusions 
The main findings of this study are: 
 
• Hyaluronan synthesis is regulated by the cellular content of its UDP-
GlcNAc and UDP-GlcUA precursors 
 
• Dynamic changes of cellular UDP-GlcNAc content feedback regulate 
HAS expression 
 
• The normal contents of UDP-GlcNAc and UDP-GlcUA in different cell 
types positively correlate with HAS1, HAS2 and GFAT2 expression, 
but not with HAS3, GFAT1 or UGDH 
 
• High content of UDP-precursor sugars are required for active 
hyaluronan synthesis by HAS1, while HAS2 and HAS3 are less 
sensitive to substrate availability 
 
• Mannose is a novel hyaluronan synthesis inhibitor and it has an anti-
inflammatory effect 
 
• Inflammatory stimulus, ER-stress and hyperglycemic conditions 
induce expression of hyaluronan cables in rat epidermal keratinocytes, 
promoting their capability to bind monocytes 
 
 
This study discovered extensive connections between UDP-sugars, 
hyaluronan synthesis and HAS enzymes. The results show that the 
hyaluronan precursor sugars UDP-GlcNAc and UDP-GlcUA control 
hyaluronan synthesis by regulating HAS gene expression and acting as 
substrates to HAS enzymes. HAS1 especially needs high levels of substrates 
for active hyaluronan synthesis. The study also discovered a hyaluronan-
mediated inflammatory reaction between leukocytes and keratinocytes. 
In the future, studies of hyaluronan synthesis regulation should also focus on 
UDP-precursors. Hyaluronan synthesis seems to be very sensitive to changes 
in precursor contents, which provides new mechanisms to control 
unbalanced hyaluronan synthesis in pathological processes such as malignant 
tumors and inflammation. For example, mannose was found to deplete UDP-
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GlcNAc, resulting in a reduced rate of hyaluronan synthesis and inhibiting 
granulation tissue growth and leukocyte accumulation in wounds in vivo. 
This suggests that hyaluronan synthesis is an important contributor in 
inflammation, and that mannose is a potential anti-inflammatory agent. 
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Synthesis by UDP-sugars
The thesis showed that the rate 
of hyaluronan (HA) synthesis in 
different cell types correlated with 
the cellular content of UDP-GlcNAc 
and UDP-GlcUA. UDP-GlcNAc 
controlled HA synthesis as a critical 
substrate for HA synthases (HAS1-3) 
but also by regulating HAS expression 
through O-GlcNAc modification of 
transcription factors. Mannose was 
found to inhibit HA synthesis by 
UDP-GlcNAc depletion. This novel 
inhibitor blocked HA-dependent 
monocyte binding to keratinocytes, 
induced by inflammation, and 
prevented leukocyte accumulation 
and growth in wound tissue. 
 
